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iSUMMARY
In the present study the role of glucagon in normal physiology
was re-examined. Neutralisation of endogenous glucagon by glucagon
antibodies was used as a tool in unravelling glucagonfs role in
glucose homeostasis. Glucagon did not prove to be that important
for the maintenance of basal blood glucose levels in fasting rats.
Its contribution in the recovery from insulin-induced hypoglycaemia
1
was not found principal among other counter-regulatory hormones. 
However, its direct insulinotropic activity was substantiated. Rats 
given exogenous glucagon antibodies with very high affinity and 
binding capacity and rabbits immunised against glucagon showed 
impaired insulin response to arginine stimulation. From the conducted 
studies, there is evidence that glucagon antibodies can enter into 
the interstitial space of the pancreatic islets and block the 
paracrine effects that glucagon exerts on the cells of different 
type that exist in the endocrine pancreas.
The effect of L-tryptophan on A-cells of the pancreas was 
studied after oral and intravenous administration of this amino 
acid. The different pattern of glucagon response obtained could be 
attributed to the glucagonotropic activity of gastric inhibitory 
polypeptide (GIP), implicating an important role of glucagon in the 
enteroinsular axis.
The effect of adrenaline and somatostatin on the stimulation 
of insulin and glucagon by L-tryptophan was also studied. The 
inhibitory action of somatostatin on A- and B-cells of the. pancreas //. 
was confirmed -as well as the inhibitory action of adrenaline only 
on B-cells.
Finally, an immunoassay for total, glucagon-like immuno- 
reactivity was developed. Gut glucagon-like immunoreactivity 
was measured after two different meals with and without addition 
of guar gum in normal and diabetic subjects. The results could 
not exclude the possible role of gut glucagon-like immunoreactant 
as a mediator of enteroinsular axis.
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CHAPTER 1 
GENERAL INTRODUCTION
21.1 GENERAL
The evolution of higher vertebrates has been associated 
with the development of a complicated set of hormonal controls 
that monitor cell processes. The continuous activity of 
endocrine glands provides a chronic level of cellular regulation, 
whereas the capacity of the glands to secrete increasing amounts 
of hormones as needed, permits acute regulation. TJie combination 
of chronic and acute regulation at multicellular levels contributes 
to the integrated behaviour of organ systems, resulting in the 
delicate balance within the animal known as homeostasis.
This manner, in which homeostasis is attained and maintained, 
is best explained in terms of "control" theory. At all levels of 
cellular organisation, control factors influence the direction and 
route of metabolism and affect the rate of transport and synthesis 
as well as the overall metabolism of carbohydrates, fats and proteins.
1.2 GLUCOSE HOMEOSTASIS
A starting point for integrating and correlating the acute 
effects of hormones upon carbohydrate metabolism is illustrated 
by the rapid control of blood glucose concentration. The blood, 
glucose levels in postabsorptive animals are indicators of the 
overall balance of glucose production and utilisation as they reflect 
the balance between hepatic glucose release and the metabolic demands 
of other tissues under the influence of intracellular and hormonal 
controls (1 ).
In man, despite enormous differences in carbohydrate intake, 
blood glucose concentrations seldom rise above 6 . 5 mmol/ 1 after
3the largest meal, or fall below 2 mmol/ 1 even after days or weeks 
without food. The homeostatic mechanisms responsible for maint­
aining this constancy of blood glucose concentration have been 
studied intensively but are still poorly understood due to the 
inherent complexity of the problem.
1.2.1 The role of the pancreas in glucose homeostasis
f
The importance of the pancreas in the regulation of the 
blood glucose concentration has been recognised since the 
accidental and important discovery by von Mering and Minkowski (2) 
that total surgical removal of the pancreas.in the dog induces a 
condition resembling severe diabetes mellitus in man.
The isolation, purification and ultimate commercial prep­
aration of insulin confirmed the importance of the pancreas in 
glucose homeostasis. This was still further emphasised by the 
identification, isolation and purification of a second pancreatic 
hormone, glucagon, the lack of which, by pancreatectomy, leads in 
a small number of species to death from hypoglycaemia rather than 
to diabetes.
The possibility suggested by these observations of a fine 
balance between a hypoglycaemic pancreatic hormone, insulin, on 
the one hand, and of a hyperglycaemic pancreatic hormone, glucagon, 
on the other, had captured the imagination of many workers in this 
field. A bihormonal model for blood glucose regulation proposed 
by Unger (3) and its current tolerance to criticism under the light 
of more recent data from other studies as well as the present 
study, will be discussed below.
41.2.2 Anatomy of the pancreas
The pancreas is a complex, mixed exocrine-endocrine organ 
found in all but the most primitive of the vertebrates. In many 
bony fish, islet tissue forms a discrete mass anatomically 
separate from the bulk of the pancreas, but in higher vertebrates 
the islets of Langerhans, which comprise less than 1% of the total 
bulk of the pancreas, are scattered more or less evenly throughout
f
its substance.
The main venous drainage of the pancreas is into the portal 
vein, though small retroperitoneal anastomoses between portal 
tributaries and systemic veins may occur. Lymphatic drainage is 
directly into the thoracic duct. Thus the possibility exists that 
pancreatic secretions may in some circumstances gain direct access 
to the systemic circulation without prior passage through the 
liver (4).
There are approximately one million islets in the average 
human pancreas, each of which is roughly spherical and varies from 
50-400 y in diameter. With the use of classical histological 
histological stains, three main types of cell can be recognised: 
alpha (A) , beta (B) and delta (D). In man, the B-cells are the 
most numerous, the D-cells the least. In adults the B- to A-cell 
ratio is about 2 :1 .
In man, the different islet cell types are evently distrib­
uted throughout the islet and they in turn are evently distributed 
throughout the pancreas. This is not true of all species, as in the 
duck there is an overall preponderance of A-cells, and the 
individual islets are more or less exclusively of A- or of B-cells
and in the dog the islets of the uncinate process are composed 
almost entirely of A-cells.
1*2.3 Microanatomy of the islets of Langerhans
Special anatomical features within the islets may be 
essential to provide the appropriate hormonal secretions that 
regulate fuel disposition.
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The first structural feature that demands attention is the 
arrangement of islet cells into separate microorgans with a spec­
ific topography (5). Application of immunofluorescent staining 
techniques for insulin, glucagon and somatostatin in serial sections 
of human and rat islets have clearly defined the topographical 
relationships of the cells that contain these peptides as 
schematised in Fig.1.1.
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Fig.1.1
Schematic representation of the number and distribution of insulin-, 
glucagon-, and somatostatin-containing cells in the normal human 
islet (left). Large vascular channels penetrate the islets and are 
followed by glucagon- and somatostatin-containing cells (right). This 
pattern divides the total islet mass into smaller subunits, each of 
which contains a centre formed mainly of insulin-containing cells and 
surrounded by glucagon- and somatostatin-containing cells. (Reprinted 
from Orci and Unger (5)).
6The insulin-containing B-cells, which form more than 60% of 
the islet cell; population, are arranged in a relatively homogeneous 
central mass. The glucagon-containing A-cells are situated at the 
periphery of the islet in a thin external mantle, often only one 
cell in thickness and, in man, penetrate the interior of the islet 
only along the main vessels. Between the outer rim of A- and the 
B -cell core are scattered somatostatin-containing D-cells whichI
form approximately 1 0 % of the total immunofluorescent islet cell 
population. This rim is the only region of the islet in which all 
three cell types are in contact with each other. It is in this 
tricellular region that afferent vessels and nerves enter the islet.
It may be functionally important that almost all A-cells have 
contact with one or more of the other cell types, as do D-cells, 
whereas the vast majority of B-cells have contact only with other B- 
cells. Perhaps this heterogeneous cortical area of the islet is the 
site of local interactions such as the insulin-g.lucagon feedback 
loop, first proposed by Samols et al (6 ) and the lately postulated 
local inhibiting effects of somatostatin. This region may be the 
locus of the quick sensors of the islet, those that respond within 
seconds to various stimuli.
A third structural feature recently demonstrated at the electron 
microscopic level are membrane specialisations, tight junctions, 
and gap junctions (7).
1.2.3.1 Tight junctions
Tight junctions consist of linear points of fusion between 
the outer leaflets of the plasma membranes of adjacent cells.
They are not stable structures, but rather are undergoing constant 
remodelling.
The function of these structures remains to be determined, 
but it seems that they create compartments or zones within the 
intercellular space (7). It has been suggested (8 ) that partit­
ioning of the intercellular space may help direct endocrine secret­
ory products towards the efferent capillaries and prevent unintended 
interactions with neighbouring cells. On the contrary, secretory 
products intended for local action only, as may be the case with 
somatostatin, would be directed only to local targets and prevented 
from escaping into the circulation, where versatile effects might 
result in unintended actions on remote target organs.
1.2.3.2 Gap junctions
A second membrane specialisation of the islet cells, recently 
identified are the gap junctions (7) (8 ), low resistance pathways
through which small molecules may pass from one cell to another 
without entering the intercellular space. These structures are 
present not only between B-cells and B-cells and between A-cells 
and A-cells, but also between A-cells and B-cells.
It has been suggested (9) that the organisation of these 
cells into discrete microorgans with special cellulal and sub- 
cellular interrelationships may be critically important for the 
metabolic functions served by the properly coordinated release 
of their secretory products. When the islets malfunction, as 
they do in severe diabetes, this anatomically organisation may be 
totally disrupted.
81. 2 . 3. 3 Neurovascular elements
The islets of Langerhans are richly innervated by both vagal 
and sympahtetic post-ganglionic nervous terminals. Though long 
recognised by anatomists, their potential physiological significance 
has only lately received recognition.
The existence of the anatomical features within the islets,
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as described above, and their functional implications in relation to 
the distribution of neurovascular elements, is the entrance of 
afferent blood vessels and nerves in the tricellular area of the 
islets. This could signify that this region is designed to receive 
the neural and blood-borne signals that influence the responses 
of the remaining regions of the microorgan, and that pejrhaps it 
constitutes the so-called "pacemaker" area (1 0 ).
1.2.4 Insulin
Insulin, the secretory product of B-cells of the islets of 
Langerhans, is at the centre of metabolic regulation and its role 
in glucose homeostasis is principal in mammalian species.
The elucidation of the chemical structure of insulin and its 
total synthesis from amino acids has led to a clear understanding 
of the differences between insulins prepared from the pancreas of 
different species (11). Insulins are proteins consisting of two 
polypeptide chains cross-linked by two disulphide bonds. The shorter 
A has 21 amino acid residues, the longer B having 30 residues.
Insulin is synthesised in the ribosomal fraction of the B- 
cell and stored in the B-granules which are seen in abundance in
pancreatic islets of resting animals, while, after stimulation, 
differing degrees of degranulation are detected.
1.2.4.1 Secretion of insulin
The major advance which made it possible to define the 
insulin-secretory process in detail, both in vitro and in vivo, 
was the monumental work of Drs. Yalow and Berson in the development 
of the radioimmunoassay technique for the measureme'nt of insulin
(12). The development of the double-antibody immunoassay technique
(13) made it possible for a number of laboratories to measure 
insulin quite readily.
There is quite persuasive evidence that there are receptors 
on the membrane and probably elsewhere in the cell, which can inter­
act with glucose or amino acids and trigger insulin.release (14). 
Nonmetabolisable amino acids can promote insulin secretion, and 
there is no correlation between the magnitude of amino acid metab­
olism and insulin secretion (15) (16). Moreover, evidence has been
accumulated which demonstrates that while glucose metabolism may be 
of importance for the islet, glucose appears to bind to a specific 
membrane receptor in inducing insulin secretion (14). It must 
be noted that this issue is still unsettled, as a number of studies 
have emphasised the importance of islet glucose metabolism as an 
integral part of the secretory process (17) (18) (19).
The cation requirements for insulin release have been desc­
ribed, and it seems clear that potassium and calcium are critical 
in limiting or promoting insulin secretion (20) (21). Malaisse
et al (2 2 ) have demonstrated clearly that at the time of insulin
release, there is a decrease of calcium efflux, suggesting that 
cellular translocation of calcium has occurred which may be related 
to microtubule contraction.
There is also an ample body of evidence indicating that the, 
process of insulin release requires energy, so that the production 
of ATP has to be considered, at least as a permissive factor (23).
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The secretory response of the B-cell is characterised by its 
rapidity and sensitivity. It has been suggested that insulin 
release occurs in packets, as a certain threshold level of stimulus 
is reached (24). With prolonged glucose infusions, two peaks 
of insulin release have been observed (25) (26). Although these
peaks have been variously referred to as two compartments, two pools 
of insulin, it is not clear as to whether or not these represent 
separate anatomical or biochemical entities. It is of particular 
interest that sulfonylureas seem preferentially to stimulate the 
initial peak.
1.2.4.2 Action of insulin
An important aspect of insulin that has engaged the interest 
of many investigators since its original isolation, is the 
seemingly impenetrable problem of its mechanism of action.
The major biochemical processes whereby actions of insulin 
are manifested have been known for a long while and include membrane 
transport of glucose, amino acids, and certain ions, increased 
storage of glycogen and formation of triglycerides, and stimulation 
of protein, RNA and DNA synthesis.
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The classic studies of Levine (27), Park (28) and Crofford (29) 
focused attention on the concept that insulin acts directly on the 
plasma membrane of target cells, altering their permeability and 
transport mechanisms. Subsequent studies and recent work on insulin 
receptors of isolated plasma membranes and cells confirmed these 
actions of insulin, although it is still unclear how the insulin- 
receptor complex activates membrane transport processes (30).
i
Additional evidence has been accumulating, however, suggesting 
that the intracellular effects of insulin cannot be accounted for 
simply by effects of insulin on the transport of substrates into 
the cell. Thus, it is inferred that insulin generates a signal that 
is propagated by the cell to the enzyme systems. Insulin and its 
receptor are presumed to interact and remain in the extracellullar 
or plasma-membrane phase while the second, messenger, first intro­
duced by Sutherland and colleagues (31), relays the signal into 
the cell's interior.
A possible way of integrating the uptake and degradation 
of insulin with its biological action, supported by evidence obtained 
lately that specific cell-surface receptors have a role in the 
uptake of numerous proteins by cells, is the receptor/transducer/ 
internalisation model proposed by Steiner (32). According to 
this, receptor-bound insulin must be internalised via its receptors 
in order to reach intracellular or intramembranous sites of 
degradation.
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1.2.5 Glucagon
Glucagon, the secretory product of A-cells, for long the 
poor relation of the pancreatic hormones, has received wide 
attention over the past few years, largely through the work and 
stimulus of Unger and his group (33). First recognised as a 
hyperglycaemic contaminant of commercial insulin preparations, 
it was given its name by Murlin et aJL (34) in 1923, but it was
f
nearly 30 years later that glucagon was isolated (35) and 
Sutherland showed that it stimulated hepatic glycogenolysis (36)*
Because of its powerful pharmacological effects, glucagon 
was generally accepted as being concerned wdLth the regulation 
of glucose homeostasis, acting in an opposing manner to insulin.
Glucagon is a polypeptide containing 29 amino acids, the 
arrangement of which excludes any chemical relationship with 
insulin but suggests a strong relationship to secretin. It has 
a molecular weight of 3485, its amino acid sequence is known 
and subject to species variations.
Recent interest in glucagon dates from the finding of highly 
specific antisera which allowed accurate measurement of pancreatic 
glucagon in peripheral venous blood in man. It was then suggested 
that glucagon is as important as insulin in blood glucose homeo­
stasis (37) and that diabetes is as much a disease of glucagon 
excess as of insulin deficiency (38).
1. 2.5.1 Secretion of glucagon
Many factors stimulate glucagon secretion, such as amino 
acids, particularly alanine (39), hypoglycaemia (40), cyclic
13
AMP (41), the gut hormones, gastrin, pancreozymin-cholecystokinin, 
VIP and gastric inhibitory polypeptide (GIP) (42) and neurotensin 
and substance P (43) , while glucose (44), fatty acids, ketone 
bodies and secretin inhibit secretion. Intensive physical exercise 
also stimulates glucagon release in rats, dogs and man, possibly 
through activation of the sympathetic nervous system (45).
Secretion of glucagon is further modulated by hormones such 
as catecholamines and cortisol which increase secretion, and by 
neural stimuli.
The rate of pancreatic glucagon secretion in man is extremely 
small when compared with the doses of glucagon previously employed 
to study the metabolic effects of this hormone. Basal secretory 
rates of glucagon in normal man are not greater than 100-150 Pg/day 
(46). These values are probably an overestimate when one takes 
into account that portion of glucagon immunoreactivity that is not 
biologically active (47). Thus, earlier studies employing bolus 
injections of as little as 0 .1 mg of glucagon are clearly 
pharmacological. On the basis of these observations and the small 
portal-peripheral gradient for glucagon (as compared with insulin) 
the molar ratio of pancreatic insulin and glucagon secretion is 
actually about 8-12:1 (48) rather than 3-4:1 as determined by 
circulating peripheral hormone levels.
1.2.5.2 Action of glucagon
Many actions are attributed to pancreatic glucagon, some 
of which are physiological and some pharmacological. In order 
to determine whether the action is physiological, various criteria 
have to be satisfied. It is now realised that glucagon circulates
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in concentrations ranging from 20 to 500 pg/ml (49). Any action, 
therefore, which is considered to be physiological must be shown 
to occur within this range of values. Because of species 
variations, a result in an animal study may not necessarily be 
extrapolated to man.
Glycogenolysis. Glycogenolysis was one of the first actions 
attributed to glucagon and the one after which it was named.
The glycogenolytic activity of glucagon is achieved through its 
action on adenyl cyclase responsible for the synthesis of cyclic 
3',5'-AMP and through a chain of events which lead to the 
ultimate release of glucose from the liver. Glucagon has been 
reported as the most potent hepatic glycogenolytic agent known 
(50). It produces glycogenolysis in every species studied (50) 
and it does this at very low hormone concentrations. The minimum 
concentrations of glucagon required to prochce glycogenolysis are 
between 50 and 100 pg/ml. This is considerably less than even 
the lowest estimates for the concentration of glucagon in 
pancreaticoduoduodenal blood - though not lower than some estimates 
of glucagon in peripheral venous blood. However, a more assiduous 
judgement of how physiological the action of glucagon on glyco­
genolysis could only be drawn from experiments in which insulin 
is also present into the portal vein of the perfused liver at 
the time that glucagon is injected and in molar ratio close to 
that normally found in the portal circulation.
The first step in the actual mechanism through which 
glucagon stimulates hepatic glycogenolysis is its binding to 
specific receptors that are carried by liver cell membranes (51).
This results in activation of the membrane-bound adenyl cyclase 
system which, as mentioned above, is responsible for the synthesis 
of 3',5'-AMP and a chain of events leading to release of glucose.
Gluconeogenesis. Glucagon also has important actions on hepatic 
gluconeogenesis. Its action is mainly on the rate at which 
various substrates such as amino acids, lactate and pyruvate are 
extracted from the blood and converted to glucose., Unlike glyco­
genolysis, the action of glucagon on gluconeogenesis is persistent 
and appears to be mainly involved in amino acid metabolism. 
Administration of glucagon has been shown to cause a fall in total 
plasma amino acid concentration, which has been attributed to 
glucagon-stimulated hepatic extraction from the circulation (52) 
and it has been shown that glucagon stimulates transport of amino 
acids to the liver, especially alanine (53), the largest 
contributor to glucose production from amino acids (54).
Gluconeogenesis is also mediated by cyclic AMP, and all the 
effects of glucagon on hepatic gluconeogenesis are counteracted 
by insulin.
Lipolytic effect. In adipose tissue of most animal species, 
glucagon stimulates lipolysis, again through an effect of cyclic 
AMP, this time on hormone sensitive lipase.
Chicken adipocytes are extremely sensitive to the lipolytic 
effect of glucagon, as insulin has no antilipolytic effect on 
adipose tissue in birds (unlike in mammals), but this effect has 
not been found with human fat cells at physiological 
concentrations (55).
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Insulinotropic effect. Saraols et al (56) were the first to 
demonstrate that glucagon is an extremely potent stimulus to 
insulin secretion. This initial observation was amply confirmed 
by Crockford et aJL (57) and others using in vitro preparations 
(58) (59) .
That this effect on insulin secretion might indeed be 
physiological, was supported by the work of Ketterer ejt ol (60) , 
when these workers infused tiny physiological doses of glucagon 
via the portal vein in dogs and showed that this was sufficient 
to produce insulin secretion.
The insulinotropic effect of glucagon is enhanced by 
existing or recent hyperglycaemia and is reduced, or abolished, 
by any manoeuvre that reduces intra-B-cell glycogen. It is 
diminished or abolished by the addition to the medium of 
competitive inhibitors of glucose metabolism, such as manno- 
heptulose or 2-deoxyglucose, of A-adrenergic stimulators such 
as adrenaline and noradrenaline (61), the benzothiadiazine 
inhibitor of insulin secretion, diazoxide, and the phosphodiester­
ase activator, imidazole (62). All of these substances exert a 
similar inhibitory effect upon glucose-induced insulin secretion 
in vitro.
1.2.5.3 Physiological role of glucagon
Despite the plethora of data - a large amount of which is 
contradictory - that has accumulated in recent years about 
glucagon's physiological role based on its four main actions 
described above, which of those is the most important physiologically 
is still undetermined. It seems unlikely that it is the same in 
every species.
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1.3 PHYSIOLOGICAL ROLES OF GLUCAGON AND INSULIN IN GLUCOSE
HOMEOSTASIS
The intimate relation of the A-cell to the B-cell and the 
opposing effects of glucagon and insulin led inevitably to the 
concept that they function as an opposing pair (63), with insulin 
acting as an anabolic hormone, and glucagon as a catabolic 
hormone.
/
The concept of an A-cell-B-cell bihormonal unit had its 
roots in classic studies by Park and Exton (64) and Mackrell 
and Sokal (65), in which the net biological antagonism of insulin 
and glucagon to hepatic glucose metabolism was established in 
vitro. The concept assigns to the islets of Langerhans the role 
of regulator of metabolic traffic throughout the body, with 
glucoregulation taking precedence over regulation of other fuels 
because of the glucose dependence of the CNS under normal 
circumstances.
Unger, putting forward a bihormonal theory for glucose 
regulation, claimed that only by means of a “push-pull" system 
is it possible to limit concentration changes of a substance 
travelling through a space at greatly changing flux rates, and 
that this could consist of glucagon, regulator of endogenous 
glucose influx into the extracellular space, and insulin, regulator 
of glucose efflux from that space, operating in properly coordinated 
coupled fashion.
Later, when it was realised that carbohydrate is not the 
sole stimulus to insulin secretion but amino acids, as well as 
other secretagogues, had insulin-releasing activity, this theory
had to be modified in order to survive. This time the molar 
ratio of insulin to glucagon was proposed (6 6 ) as the most 
valid index of the functional activity of the bihormonal unit, 
consisted of A- and B-cells. This more elaborate and flexible 
hypothesis could explain the response'of the bihormonal 
functional unit after any nutrient flux. In the case of amino 
acids, it proposes that during a protein meal or an amino acid
i
infusion, glucose efflux is increased as the result of aminogenic 
insulin stimulation;'but the molar ratio of insulin to glucagon 
alters in such a way that hepatic glucose influx is also 
increased, guided by aminogenic glucagon secretion. In the 
absence of this alteration in molar ratio of insulin to glucagon, 
glucose levels would predictably decline.
The above mentioned theories on glucose regulation received 
a severe jolt when it was shown that glucose is not the only, nor 
indeed the most potent, regulator, of insulin secretion, and.that 
glucagon, far from ‘[stimulating insulin secretion solely by causing; 
hyperglycaemia, had a direct stimulatory effect upon the B-cells 
of the pancreas (56). The importance of this latter observation 
increased when it was realised that because of the morphology of 
the islets of Langerhans in man, the pancreatic B-cells may possibly 
be bathed in fluid many orders of magnitude richer in glucagon than 
any other cells of the body. A hypothesis was then proposed 
according to which a major role of glucagon in man is to regulate 
insulin secretion in response to the ingestion of food without 
the necessity for comparatively large changes in substrate 
concentration in the blood. According to this, glucagon acts as 
a signal sensor and amplifier of certain stimuli to insulin
secretion, increasing enormously the sensitivity of the insulin- 
secreting system to insulin requirements.
Applied to the glucose regulation mechanism, this latter 
hypothesis implies that there is only a primary insulin-glucagon 
negative feedback system, with insulin suppressing glucagon and 
glucagon stimulating insulin secretion (Fig.1.2),
G L U C A G O N
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Principle of insulin-glucagon negative feedback system. Insulin 
suppresses glucagon while glucagon stimulates insulin secretion. 
(Reprinted from Samols et a^ (6 )).
and not two separate servo-systerns, i.e. negative insulin/glucose 
or glucose glucagon feedback system as had been accepted by 
previous theories.
Up to now, none of the above theories on the inter­
relationships of glucagon and insulin in glucose homeostasis has 
been generally accepted and this leads to big controversies when 
the role of glucagon in the pathogenesis of diabetes mellitus is 
assessed (67). Arguments about "unihormonal abnormality" and 
"bihormonal abnormality" have their roots on the uncertain
physiological status of glucagon and its still undetermined role 
in conjunction with insulin on glucose regulation.
1.4 ENTEROINSULAR AXIS AND ITS IMPORTANCE ON GLUCOSE
HOMEOSTASIS
It has been known for a very long time that much larger 
amounts of glucose can be given orally than intravenously 
without production of glucosuria. Revival of interest in the 
differences of oral and intavenous glucose tolerance commenced 
with the availability of the radioimmunoassay for insulin and 
the application of insulin estimation to this problem in 1964 
by McIntyre and colleagues (6 8 ). A much greater response was 
observed after an oral load than after intravenous injection of 
the same amount of glucose, despite a smaller increase of the 
blood glucose level. It was estimated that half of the insulin 
secreted after an oral glucose load was released by gastro­
intestinal factors (69).
The identity of the main hormone responsible for the 
intestinal regulation of insulin release and the extent to 
which it is involved, especially in diseased states, has been 
the subject of controversy. Established gut hormones, i.e. all 
peptides with effects on gastrointestinal functions, have been 
tested for their insulin releasing potency. Many of them 
stimulate insulin secretion in vivo and in vitro. However, a 
peptide qualifying for mediator of the enteroinsular axis must 
stimulate insulin release in physiological doses and must 
respond to nutrients, especially glucose. The only established 
gut polypeptides released by glucose are GIP, gastrin and gut 
glucagon-cross-reacting material or GLI (70)..
The effect of the currently favoured mediator of entero­
insular axis, GIP, on the pancreatic islets and the release of 
this peptide are regulated in a way which links gastrointestinal 
functional and metabolic need closely together. However, the 
exact mechanism of the stimulatory effect of gut hormones on 
insulin and glucagon secretion is still unknown. Indirect evidence 
that the intestinal insulin-releasing hormones, and particularly 
GIP, possess the ability to stimulate glucagon secretion by direct 
action which in its turn would be an extremely potent local 
(paracrine) stimulus to insulin release, especially in the 
presence of some hyperglycaemia (71), needs more support in order 
to clarify their mode of action.
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CHAPTER 2
GLUCAGON-LIKE IMMUNOREACTANTS AND DEVELOPMENT OF 
A RADIOIMMUNOASSAY FOR "TOTAL" GLUCAGON-LIKE 
IMMUNOREACTIVTTY
2.1 Introduction
The application of the principles of radioimmunoassay to 
the measurement of glucagon in blood led to the discovery of a 
cross-reacting material in the gastrointestinal tract. The term 
"glucagon-like immunoreactivity" (GLI) originally proposed by 
Unger et al (72) to distinguish this glucagon-like immunoreactant 
material present in extracts of gastrointestinal tissues from 
immunoreactivity of pancreatic origin, applies to any material 
preventing binding of radioiodinated glucagon to antiglucagon 
sera under specified conditions (73). If for immunochemical or 
other reasons this activity is thought to come from the gastro­
intestinal tract it is occasionally called gastrointestinal GLI 
or gut GLI.
However, it was several years before radioimmunoassay 
techniques were introduced, that the presence of a hyperglycaemic- 
glyc^genolytic factor in che mucosa of the digestive tract was 
first demonstrated by Sutherland and de Duve (74) in 1948 and 
consequently confirmed by Makman and Sutherland (75).
2.1.1 Historical
The observation by Samols et: aJL (76) that the oral 
administration of glucose caused an apparent increase in 
circulating glucagon levels measured by an antiglucagon serum 
and not a decrease as the prevailing hypothesis demanded, caused 
moments of uncertainty regarding the physiologic role of glucagon. 
However, later immunologic studies by the same authors (77) and 
others (78) ( 72) established that the gut contains and releases
a material that reacts with most glucagon antibodies and that 
the increase observed to follow oral glucose ingestion was due 
to glucagon cross-reacting materials rather than to glucagon 
itself. This uncertainty was further dispelled when another 
antiserum was reported by Eisentraut ejt aJL (79). that cross­
reacted very weakly with gut GLI and detected a decline in 
glucagon secretion induced in normal human volunteers by means 
of a large carbohydrate meal (80). It was then realised that 
the presence of this gut GLI presents a formidable obstacle to 
accurate quantitation of the pancreatic hormone in biological 
fluids, as with certain antisera as high as 90% of the plasma 
"glucagon" immunoreactivity detected was derived from the gut 
rather than from the pancreas, obscuring changes in the levels 
of the pancreatic hormone by the high background levels of the 
gut cross-reactant.
Since then, much effort has been devoted to elucidating 
the nature of this cross-reactant, although the theories that 
have been proposed from time to time regarding the action of 
this material have outstripped the real advances in knowledge 
concerning its chemistry and biological activities.
2.1.2 Origin
Since glucagon-like immunoreactivity is present within 
the gastrointestinal tract, considerable effort has been expended 
to identify cells of the gastrointestinal mucosa equivalent to 
islet A-cells;. (Orci et_ al, 1968 (81) , Forssraan e_t aT, 1969 (82 ) / 
Vassalo et a3L, 1969 (83), Kobayashi et aJL, 1970 (84)). It is, 
however, difficult to evaluate the histological evidence for
the existence of a specific cell type in the gastrointestinal 
tract that synthesises, stores and secretes gut GLI partly 
because there is no known way in which the origin of an 
unidentified activity can be unequivocally attributed to any 
one cell.
Polak and colleagues (85) have demonstrated cells that 
bind fluorescent antiporcine glucagon gamma globulin in dog 
stomach and in all regions of the intestinal tract, with the 
exception of the pylorus and duodenum. The cells were termed
by these workers enteroglucagon cells. The highest concentration
of enteroglucagon (gut glucagon-like immunoreactivity) was found 
in the ileum and colon (86)t where the greatest number of 
enteroglucagon cells has also been encountered by Larsson et: a_l 
(87). Only one type of enteroglucagon cell has been found, 
suggesting that the multiple forms of enteroglucagon, like those 
of gastrin, are variants of a single hormone released 
simultaneously from a single cell.
Lately, another extrapancreatic source of glucagon-like 
immunoreactivity was reported to be the salivary gland.
Lawrence ejt al (8 8 ) found tha t hornogenates of rat, mouse, rabbit 
and human submaxillary salivary glands contained a significant 
quantity of a material with glucagon-like immunoreactivity.
And although serial dilutions of this material showed identical 
immunoassay curves when measured with the Unger K-30 glucagon 
antiserum, an antiserum claimed to be pancreatic specific, they 
might behave differently in a system using a more specific 
antiserum.
Estimation of the GLI content of various segments of 
the human digestive tract is given in Table 2.1. Out of a 
total of 132 jig Eq in the whole tract, small amounts were 
found in the oesophagus, pylorus, and duodenum, and large 
amounts in the ileum (57 yg Eq) and colon (55 pg Eq) although 
these results can only be interpreted as semiquantitative, 
because the antibodies used had less affinity for the guti
material than for the pancreatic glucagon used as standard 
(89).
2.1.3 Cytology
Identification of the cell from which gut glucagon-like 
immunoreactivity is originating was reported in 1971 by Polak 
et al (9 3) (85) t and combined quantitative immunochytochemistry
and radioimmunoassay of tissue extracts showed that the largest 
quantities of gut GLI are found in the ileum (15.7 cells per
2 2
mm ) and in the colon (24,74 ce?.ls per mm ).
There are two different types of immunoreactive glucagon 
cells in the gut. One of these, the gastric A cell, is well 
represented in the oxyntic mucosa of the dog, but poorly 
represented or absent from the stomach of most other species 
(9 4). This cell is closed with respect to its gland lumen, 
so that it is lacking apical projection with capping tuft of 
microvilli, and it possesses all of the staining and ultra- 
structural characteristics of the glucagon producing pancreatic 
A cell. The other, intestinal L or gut glucagon cell (Lausanne 
1977 classification of gastroenteropancreatic endocrine cells) 
is well represented in the intestine of all species so far
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Table 2.1 Glucagon-like immunoreactivity (GLI) content of 
the pancreas, the salivary glands and the gastrointestinal 
tract in man according to several different studies.
GLI (ng Eq/g wet tissue) References
Pancreas 1500 Assan et a_l, 1969 ( 90)
100-900 Unger et al_, 1966 (91)
3700 Buchanan jet aJL, 1967 (78)
Salivary glands
f
Submaxillary 20 Lawrence jat ail, 1977 (8 8 )
Sublingual 7 Lawrence et aJL, 1977 (88 )
Parotid None Lawrence e_t a l , 1977 (8 8 )
Oesophagus 29 Schopman et aJL, 1967 (89 )
2 Bloom et aJL, 1975 (92)
Stomach 4 Unger jet aJL, 1966 (91)
5 Assan et_ a]L, 1969 (90)
2 Bloom et - al, 1975 (92)
Antrum 50 Schopman et al, 1967 (89 )
Fundus 42 Schopman et all, 1967 (89 )
Pylorus 30 Schopman et ajL, 1967 (89 )
Duodenum 4 Unger et aJL, 1966 (91)
50 Schopman jet a3^ , 1967 (89 )
2 Bloom et al, 1975 (92)
J e j unum 9 Unger 'jet all, 1966 (91)
60 Schopman et a_l, 1967 (89 )
290 Buchanan et al, 1967 (78)
160 Bloom et al_, 1975 (92 )
Ileum 32 Unger et a^, 1966 (91)
130 Schopman et al, 1967 (89 )
770 Bloom et al, 1975 (92 )
Colon 75 Unger et al, 1966 (91)
6 -10 Samols et a3., 1966 (77)
141 Schopman et al, 1967 (89 )
Bloom et al, 1975 (92)
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investigated, particularly in the distal small intestine and 
colon. It reaches its gland lumen, terminating in distinctive 
microvilli, and differs sharply from both pancreatic and gastric 
A cells. This information is in agreement with that obtained 
by immunoelectron cytochemistry, using resin-embedded semithin- 
thin serial sections (95).
2.1.4 Chemistry
t
The glucagon-like substances of gastrointestinal origin 
have not yet been chemically identified. But gut GLI probably 
has a part of its amino acid sequence in common with glucagon 
and is, therefore, able to react with many antibodies against 
pancreatic glucagon (96).
Several attempts have been made to isolate the gut GLI. 
Valverde et a_l (97) found GLI in the dog jejunum to reside in 
two peaks on gel-filtration, peak II having a molecular weight 
similar to pancreatic glucagon and peak I being considerably 
larger. GLI isolated from pig ileum by Murphy et al (98) 
appeared in two major peaks on gel-filtration, one peak having 
a molecular weight of about 12.000 and the other a molecular 
weight of 3500, although on polyacrylamide gel electrophoresis, 
the large molecular weight GLI resolved into three further 
bands. Later work by Moody ejt al (99) reports that the 
majority of the gut GLI extracted from the intestine have a 
molecular weight of 10.000 or over, but some (perhaps 25%) have 
a similar filtration size similar to that of glucagon.
A pure gut GLI was isolated from the large molecular 
weight gut GLI of the porcine intestine by Sundby et al (100) »
The gut GLI was isolated from an acid-alcohol extract of frozen 
porcine small intestine and was selected for isolation because 
it formed over 40% of the gut GLI in the extract. The protein, 
initially called porcine gut GLI-I, has 100 amino acids and 
contains all the amino acids found in porcine glucagon. The 
name "glicentin" was proposed by F. Sundby for this protein 
("gli" for glucagon-like immunoreactant, "cent11 for 100 amino 
acids). '
2.1.5 Immunochemistry
Radioimmunological studies by Assan and Slusher (301) 
were the first to show the presence of two antigen sites inside 
the glucagon molecule. They found that in the purified gut 
GLI only one of these sites is present. This study, which 
was done with various synthetic glucagon-rela ted peptides and 
examined their radioimmunological behaviour towards several 
distinct antiglucagon immune sera, contributed also to the 
clarification of the chemical structure of GLI as well as to 
a more accurate understanding of the cross-reaction between 
some antisera and the glucagon-like immunoreactivity.
Heding et. a_l (102) confirmed later that glucagon has two 
antigenic sites. One, situated in 24-29 amino acid position 
of glucagon, evokes the so-called C-terminal or specific anti­
sera, which react with glucagon and certain fragments of 
glucagon. The second, in 2-23 amino acid position, evokes 
the so-called N-terminal or cross-reacting antisera which 
react with glucagon and the gut peptides, "gut Glucagon-Like 
Immunoreactants" (gut GLIs), a term recently suggested by 
Moody jet aJL (9 9).
The structure of the antigenic site in glucagon in 2-23 
amino acid position is probably determined by the sequence 
glucagon (12-14). This immunodeterrainant is proposed, because 
glucagon (12-14) is the only appreciable portion of glucagon 
(2-23) that is not present in one or more of the gut peptides, 
secretin, VIP and GIP which, despite extensive similarities to 
glucagon, do not cross-react with antiglucagon sera.
2.1.6 Characterisation '
Recently, Moody et al (99) classified the extrapancreatic 
glucagon-like immunoreactivity according to its origin into : 
"gastric glucagon" and "gut glucagon-like imraunoreactants", 
te nils which according to the au the rsiWeteipref erred to the 
previously used glucagon-like immunoreac tivities, because it 
emphasises that the abbreviation "gut GLIs" refers to peptides 
containing a definite structure, and not to ill-defined 
materials which cross-react with one antiglucagon serum or 
another.
2 .1 .6.1 Gj^stric_glucagon
Substantial amounts of gastrointestinal glucagon have 
been located only in the canine gastric fundic mucosa. Morita 
et al (103) measured the glucagon content of the gastric fundic 
mucosa of five dogs with C-terminal antiglucagon sera and 
found an average of 2.2 pg/g wet weight, which was somewhat 
lower than the pancreatic content of glucagon, reported to be 
12 pg/g wet weight in the splenic portion. The same authors 
found that the canine gastric glucagon had the same apparent 
molecular size, electrophoretic mobility and immunoreactivity 
as porcine glucagon.
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Canine gastric glucagon has been partially purified by 
Srikant ^t aJL (L04) who also found that it had much the same 
immunological, chemical and biological properties as canine 
pancreatic glucagon. The gastric glucagon cells which are 
indistinguishable from pancreatic A2 cells and contain material 
cross-reacting with C-terminal specific antiglucagon sera (105) 
are probably the source of the plasma glucagon described in
t
depancreatised dogs, especially after withdrawal of insulin 
therapy as reported by Vranic et a_l (106) .
2 .1 .6.2 Gut_glucagon-like_immunoreactants
The gut GLIs are widely distributed in the post-duodenal 
mucosa and are released into the plasma by oral loads, 
particularly of carbohydrates. As mentioned above, the 
majority of the gut GLIs extracted from the intestine have a 
molecular weight of 1 0 ,000 or over, but some have a gel 
filtration size similar to that of glucagon. These small 
gut GLIs do not react with C-terminal antiglucagon sera and 
one small gut GLI has certain glucagon-like biological 
effects. It cross-reacts with the hepatic, glucagon receptor
(107) suggesting that it must have a similar tertiary structure 
to glucagon. This biologically active small gut GLI has not 
yet been isolated but it has been reported to have a basic pi
(108)resembling a GLI detected in dog pancreas by Srikant and 
Unger (109) and a proposed proglucagon fragment isolated from 
crystalline glucagon.
Glicentin, which constituted over 40% of the gut GLI in 
the extract of porcine small intestine, has been studied by
Jacobsen et al_ (110) and its sequence has been„partially 
elucidated. The C-terminus is alanine, the N-fcerminus is 
arginine and the next 12 amino acids from the N-terminus 
bear no relationship to any sequence found in glucagon. The 
sequence -Met-Asn-Thr- is the same as that of the last three 
amino acids in glucagon. Six of the other eight amino acids 
in the seauence are in the same position as in the proglucagon
fragment of Tager and Steiner and the other two are inverted*
with respect to the sequence of the proglucagon fragment*
The results so far available support the hypothesis that 
glicentin contains the full sequence of glucagon and (with the 
exception of an inversion of two residues) the full sequence 
of the proposed proglucagon fragment of Tager and Steiner.
Fig.2.1 depicts a schematic outline of the-known sequences 
of glucagon, a possible fragment of proglucagon and glicentin.
Glicentin was found to have full molar immunoreactivity 
with N-terminal antiglucagon sera. However, when glicentin 
was coupled to human serum albumin and injected as an antigen
in five rabbits, one rabbit gave an anti serum that would not
125 125bind I-labelled glucagon, but bound I-lafoelled gut
glicentin, suggesting that there is another antigenic site
of glicentin other than the glucagon-like site (9 9 )*
When a crude extract of porcine intestine on CM-cellulose 
was fractionated, resolved the total gut GLIs into several 
well-defined fractions, and most of these fractions contained 
equal amounts of gut GLI and glicentin-like immunoreactant 
(peptide cross-reacting with antibodies raised against the 
antigenic site of glicentin which lies outside glicentin*s
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glucagon-like antigenic site). The small basic gut GLI with 
glucagon -like biological properties was separated from other 
gut GLIs and did not contain any glicentin-like immunodeter- 
minant (112) . The bulk of the gut GLI extracted from the 
porcine intestine, therefore, has two known immunodeterminants: 
one reacting with the glucagon N-terminal antisera and the 
other reacting with antiserum raised against an antigenic 
site of glicentin other than the glucagon-like si'te.
When the distribution of glicentin was measured in the 
small intestine of a 30 kg pig by dividing the intestine into 
1 m sections and extracting each section in acid-alcohol, gut 
GLI and glicentin had very similar distributions, being low 
in the duodenum and upper small intestine and relatively 
elevated in the lower 4-5 m of the intestine (99), as shown 
in Fig.2.2.
All the above data led Moody et aJL (113) to propose the 
possible immunochemical relationship that exists between 
glicentin, smaller gut GLIs and glucagon. This relationship 
is schematised in Fig. 2.3. In this figure the immunodeterminant 
found in glicentin outside the glucagon sequence has been 
arbitrarily placed in the N-terminal portion of glicentin and 
the sequence in glicentin homologous to glucagon (23-29) is 
assumed to be masked.
2 .1 .6 .3 §aliyary_glucagon-like_immunoreactivity
The more recently discovered glucagon-like material of 
extrapancreatic origin obtained from the submaxillary salivary
g l i c e n t i  n 
(pgEqv)
g u t G L I 
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22 26
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80 85
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Fig.2.2
Distribution of gut glucagon like immunoreactants (gut GLIs) in the 
gastrointestinal tract. The figures refer to the mean whole 
thickness bowel content of extractable glicentin and gut GLIs as 
measured by radioimmunoassay in the small intestine of a 30 kg pig 
(99) .
The shading refers to total numbers of mucosal cells producing gut 
GLIs, as measured by quantitative immunocytochemistry in human 
gastrointestinal tract.
Immunodeterminant recognised by C~terminal reacting
antisera
Immunodeterminant recognised by N-terminal reacting
antisera
Immunodeterminant found on glicentin
Immunodeterminant masked
GLICENTIN 100
GUT GLIS
100
100
PRO-GLUCAGON FRAGMENT 
GLUCAGON
64
 r y v i M i y  *■■■*■■
64
100
92
23 24 29
Fig.2.3 /
The immunochemical relationship between glicentin, smaller gut GLIs 
and glucagon, proposed by F. Sundby.
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glands has not been characterised yet. The only piece of 
information existing is that extracts of the submaxillary 
glands of the rat applied to a Sephadex column (G-100; 50 
by 1.5 cm) and eluted with either 0.2 M glycine buffer, pH 
7.5, or with 0.09% NaCl yield a large immunoreactive glucagon­
like material which appears in a discrete peak of fractions 
immediately following an isotopically labelled gamma-globulin
f
marker, suggesting a molecular weight of 70,000 (8 8 )„ o f  
particular interest is that this material, despite its high 
molecular weight, it behaves in a radioimmunoassay with the 
reputedly "glucagon-specific" antiserum (K 30), as though it 
were authentic pancreatic glucagon (molecular weight 3,500).
2.1.7 Physiology
Virtually nothing is known about the physiology of gut 
glucagon-like immunoreactive material apart from the fact 
that it is released into the blood in response to ingestion 
of glucose (76) , meal (n4) or fat (115). This led to the 
suggestion that it might, like native glucagon, stimulate 
insulin secretion assuming that glucagon-like immunoreactivity 
was chemically and biologically identical with glucagon.
However, the glucagon-like immunoreactivity of molecular weight 
12,000, or so, isolated and purified by Murphy ejb aJL (98) had 
no insulin-releasing properties in rat pancreas pieces in vitro. 
Moreover, it was incapable of stimulating lipolysis of liver 
cell membrane receptors and finally failed to activate adenylate 
cyclase activity in B-cells.
Gutman <et al. (116) though, came with a strong piece of 
evidence favouring the ability of some glucagon-like
38
immunoreactivity fractions to stimulate insulin release. They 
were able to abolish the insulin-stimulatory effects of 
glucagon-like immunoreactivity-rich extracts of intestinal 
mucosa on pancreas pieces in vitro, by adding glucagon antiserum 
to the incubation medium. Since the ahtiserum was raised against 
pancreatic glucagon and was, therefore, presumably incapable of 
reacting with any of the other known insulin secretagogues 
except glucagon-like immunoreactivity, this is strong presumptive 
evidence of its insulin-stimulating properties.
The poor correlation, though, between the size of the 
rises in plasma glucagon-like immunoreactivity after various 
stimuli and the corresponding increases in plasma insulin raised 
the first arguments against glucagon-like immunoreactivity 
involvement in alimentary mediation of insulin secretion (117). 
However, since many of the observations were made on fasting 
subjects in the absence of even mild hyperglycaemia, the failure 
of glucagon-like immunoreactivity to provoke insulin secretion 
is hardly surprising.
Other factors arguing glucagon-like immunoreactivity as 
mediator of intestinal insulin release are that: (a) its
concentration in blood reaches a peak after ingestion of a 
meal long after insulin secretion has already become established; 
(b) glucagon-like immunoreactivity-free extracts of intestinal 
mucosa can be obtained that are nonetheless capable of stimulating 
insulin release; (c) the insulin-releasing property of glucagon­
like immunoreactivity, if any, has been overshadowed by the 
discovery of an extremely potent insulin-stimulating agent, the 
gastric inhibitory polypeptide (GIP).
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Bloom et al (118) observed that in situations of gastro­
intestinal hurry, when foodstuff passes unduly rapidly down the 
small intestine, a rather greater than normal rise in entero-glucagon 
occurs, possibly because a large number of entero-glucagon (EG) cells 
are stimulated, e.g. in the dumping syndrome the rise in plasma 
entero-glucagon is extremely great. A good correlation was also 
found between the rate of gastric emptying (119), the fall in plasma
volume (1 2 0 ) and the rate of rise of plasma entero-glucagon levels
1
after an oral glucose load. It has been reported that one patient 
with an enteroglucagon-producing tumour (1 2 1) showed gross intestinal 
stasis and an increase in mucosal growth (122). Studies on gut 
resected and hyperphagic animals, seem to prove that under these 
conditions the EG cells hypertrophy and the enteroglucagon levels 
rise (123). From the above data it was concluded that one physiol­
ogical role of enteroglucagon may be to prevent unabsorbed carbo­
hydrate or fat passing too rapidly down the small intestine by 
decreasing motility and another may be to improve absorption by 
increasing mucosal growth (124).
In terms of biological activity, as mentioned previously, 
canine gastric glucagon was found by Srikant ejt al to have much 
the same biological properties as canine pancreatic glucagon and 
the differences described could well have been the result of a 
minor modification of the gastric glucagon by the extraction 
procedure. The physiological importance of gastric glucagon in 
animals other than the dog remains uncertain, although glucagon has 
been found in extracts of porcine duodenum (125) and the porcine 
jejunum and ileum ( 92 ).
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One small GLI has been reported to have certain biological 
effects, as cross-reaction with the hepatic glucagon receptor 
and has been claimed to have insulin-releasing activity in dogs 
(126) .
From studies with GLI-I, the so-called glicentin,which is 
99% pure protein, it appears that it has no receptors on liver 
cells and it does not influence lipolysis or insulin secretion* 
GLI-I does, however, stimulate the glucose production from 
isolated hepatocytes, although much less potently than glucagon 
(127). This effect seems to require a degradation of the GLI-I 
molecule into fragments with glycogenolytic activity, a 
degradation which takes place almost immediately in the incubation 
mixture and since such degradation may take place in the intact 
organism also, GLI-I might be of potential importance in the 
control of glucose metabolism.
As for the glucagon-like material isolated from the 
salivary gland, so far it has been reported (8 8 ) that intravenous 
injections of this material elicits a hyperglycaemic effect 
comparable to that obtained with porcine pancreatic glucagon and 
that insulin release in response to the induced hyperglycaemia 
was similar in both groups of animals. Although the physiological 
role of the glucagon-like material isolated from the salivary 
glands, if any, is open to speculation, it could seem likely, as 
Lawrence et aJL suggested, that the submaxillary glands are the 
source of circulating glucagon in pancreatectomised and 
eviscerated rats.
2.1.8 Pathophysiology
As too little is known for the physiology of gut glucagon­
like immunoreactivity, its pathophysiology is less known. The 
only case in which gut GLI has been implicated as the cause of 
pathological condition was the one reported by Gleeson et aJL (122) . 
They had the opportunity to study a patient with an endocrine 
tumour in the kidney which presented with mild diabetes mellitus,
r
gross enlargement of intestinal villi, intestinal stasis and 
malabsorption; immunological studies of the tumour suggested 
that it contained material resembling gut GLI more than pancreatic 
glucagon. The GLI from the tumour did not stimulate insulin 
secretion or cause hyperglycaemia. If this tumour proves to be 
a species of gut GLI, standarising the tumour material with 
known gut GLI species once standard materials of gut GLI are 
available, it would strongly suggest that the actions of GLI may 
be related to trophic actions in the gut, motility and absorption.
The role of GLI in the pathophysiology of dumping syndrome 
is more uncertain. It was reported by Vance ejt al. (128) and 
Shima jet aJL (129) that patients who had been gastrectomised had 
elevated glucagon levels in the circulation after oral glucose 
administration and it was found by Buchanan (130) that the 
glucagon which rises in these subjects is N-terminal GLI. The 
levels were significantly higher in those patients who had the 
symptoms of the dumping syndrome. Until the actions of GLI from 
the gut are known, the meaning of these changes in the dumping 
syndrome cannot be explained. The GLI may be acting to produce 
symptoms of dumping or it may be rising in a compensatory manner 
to prevent the symptoms of dumping.
There is no conclusive evidence that gut GLI, rather 
than other known gastrointestinal hormones, influences glucose- 
induced insulin release but no proof exists either that gut GLI 
does not contain any insulin-releasing activity after an oral 
glucose load. So the role of pathophysiology of gut GLI in 
diabetes mellitus and particularly in the maturity onset type 
of it, is open to speculation.
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2.2 RADIOIMMUNOASSAY FOR TOTAL GLUCAGON-LIKE IMMUNOREACTIVITY
Using an N-terminal glucagon antiserum, it has been possible . 
to develop a radioimmunoassay measuring "total" glucagon-like 
immunoreactivity (GLI) in plasma. The object of this work was 
to enable us to determine gut iramunoreactive glucagon, by combining 
this assay with a specific assay for pancreatic glucagon which has 
already been developed in our laboratory, since a basic knowledge 
of this subject is helpful in understanding the problems posed by 
the existence of gut immunoreactive glucagon and the physiological 
role, if any, of this entity.
2.2.1 Materials and Methods
As assay buffer, 0.04M phosphate, pH 7.4 was used. . This 
was prepared by weighing out:
23.00 g disodium hydrogen phosphate (anhydrous) Na^HPO^)
5.97 g sodium dihydrogen phosphate dihydrate (NaH2P0 4 .2H20)
1.25 g thiomersalate (Merthiolate, Eli Lilly and Co.,
Basingstoke, England)
The above were dissolved in double-deionised water (which was used
for preparing all other reagents) and made up to 5 1 and the pH
was checked. The buffer was stored at 4°C and used for up to
4 months. When this buffer was used as diluent for the assay or
. 125to dilute the antiserum, the I-glucagon and the second antibody, 
2% horse serum (Wellcome No.5) was added.
Standards
As standard in the assay the WHO 1st International Standard 
for Glucagon, porcine, obtained from the MRC was used. This was
diluted in an acid alcohol mixture (1.5 ml concentrated HC1, sp. 
gr.1.18 + 75 ml absolute alcohol + 25 ml deionised water) to give 
a standard of 1 yg/ml concentration. This was stored at -20°C 
and was stable up to 4 months. For use in the assay 10 yl of 
this stock was added to 4 ml of pooled human plasma to produce 
the higher standard, i.e. 2500 pg/ml. Double-diluting this, a 
series of standard solutions were obtained and used in the assay.
i
Antiserum
Antiserum K-59 obtained from Professor K.D. Buchanan, was 
used in the assay. 1 ml of this antiserum was diluted 1:40 with 
phosphate buffer containing 0.5% human plasma protein fraction. 
Aliquots (200 yl) of this solution were freeze-dried. Each vial 
when reconstituted with 1 ml of double-deionised water gives a 
dilution of antiserum 1 : 200 containing 0 .1%  human plasma protein 
fraction.
Label
125I-glucagon tracer was prepared by a modified chloramine-T 
technique and the noniodinated glucagon component purified out by 
high resolution ion exchange chromatography on a QAE Sephadex 
column at pH 8.5 (131). After pooling of the fractions containing 
the highest radioactivity which coincides with highest immuno­
reactivity, acid alcohol (1.5 ml concentration HCl + 98.5 ml absolute
alcohol) was added in a ratio of 1:1. Stored in this way at -20°C 
125the I-glucagon was found to be stable up to 4 weeks.
125I-glucagon prepared by the "Iodogen method" was also 
tested in the system. In this method the property of a chloroglyco- 
luril) to act as an ideal electron acceptor in the iodination of
proteins and peptides is exploited (L32) .. The stability and 
sparing solubility of this chloroglycoluril in water has been 
claimed (133) to account for the minimal damage to proteins. The 
method which is very simple was as follows:
20 yl of a solution of iodogen in methylene chloride was 
spotted on to the bottom of small polypropylene tubes and they 
were placed in a 37°C bath so that the methylene chloride 
evaporated and a thin film of iodogen was formed in the bottom.
For the iodination, 10 yl of a solution of porcine glucagon,
highly purified (Novo Research Institute, Copenhagen) in O.lM
phosphate buffer was pipetted into the tube followed by 10 yl of 
125
I (1 mCi) diluted with 10 yl of O.lM phosphate buffer, pH 7.0.
The reaction was allowed to proceed for 5-15 min after which time 
0.7 ml of 0.08M Tris, 0.02 N HCl, 0.08 M NaCl, pH 8.6 buffer was 
added to stop the reaction (L34) . 5 yl of 2M Tris were pipetted
into the mixture which was brought onto the top of a QAE Sephadex 
A-25 column for the purification step. The conditions of the 
high resolution ion exchange chromatography during purification 
were exactly the same with those applied after the chloramine-T 
iodination.
Several iodinations were performed by varying the amount 
of iodogen (20 yg, 10 yg and 5 yg) , the reaction time interval 
(5 and 10 minutes) and the amount of glucagon added in the reaction 
mixture (2 and 5 yg). Each time one of these variables was 
changed while the others were kept the same.
Preparation of_ "glucagon-like immunoreactivity free plasma"
Three different preparations of " g l u c a g o n - l i k e  immunoreactivity 
free plasma" were tested.
The first preparation was a pool of plasma made free of 
"glucagon-like immunoreactivity" by prior extraction with a 
specific glucagon-like immunoreactivity immunoabsorbent. The 
methodology used was very similar to that used by Alford e_t jal 
(135) and was as follows:
200 yl of neat a±iserum K-59 were mixed very slowly with 
400 yl of ammonium sulphate saturated at 3.7°C under continuous
t
stirring on a magnetic stirrer. It was left overnight at 4°C 
and the mixture was then centrifuged at 5,000 rpm for 30 minutes. 
The precipitate was redissolved in 1 ml of O.lM sodium bicarbonate 
pH 8.0 buffer and after extensive dialysis against the same buffer 
for 48 hr. The dialysate containing about 5 mg of protein was 
coupled to 1.5 ml (wet volume) cyanogen bromide activated 
Sepharose 4B beads (Pharmacia Fine Chemicals AB, Uppsala, Sweden) 
by mixing for 18 hr at 4°C (98). The antibody-Sepharose conjugate 
was then washed alternatively with the sodium bicarbonate buffer 
(2 1 ) and distilled waLer (2 1 ) and unreacted cyanogen bromide 
groups were blocked by 2 hr incubation with 20 ml 1M ethanolamine 
(pH 8.0). The antibody beads immediately before used were washed 
extensively with alternating 0.05M acetate - 0.5M NaCl (pH 4.0) 
and sodium bicarbonate (pH 8.0) buffers.
To remove glucagon-like immunoreactivity from pooled human 
plasma 250 yl of beads and 250 yl sodium bicarbonate were 
dispensed into 10 ml of plasma, mixed by slow, end over end 
agitation for 2 hr at room temperature and separated by 
centrifugation.
The second preparation was obtained by mixing pooled human 
plasma with 20 g charcoal (Norit GSX, Hopkin and Williams) per
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100 ml plasma overnight at 4°C. The charcoal was removed by 
centrifugation followed by filtration through 6 cm Zeitz filters 
(grade HP/EKS obtainable from Carlson-Ford Ltd., Ashton-under- 
Lyne). The charcoal-stripped plasma was then inactivated by 
heating it at 37°C in a waterbath for 1 hr.
The third preparation was pooled human plasma inactivated 
only by heating it at 37°C for 1 hr.
To the "glucagon-like immunoreactivity free plasma" 
obtained by any of the above described methods, 1000 Kallikrein 
Inactivator Units (KIU) aprotinin (Novo Research Institute, 
Copenhagen) per ml were added and it was aliquoted into suitable 
volumes and immediately stored at -20°C until used.
Donkey anti-rabbit IgG was used for separation of the free 
and antibody-bound radioiodinated glucagon in a dilution of 1 : 1 0  
in 0.04M phosphate buffer containing 2% horse serum and 0.01M 
EDTA. The same batch of double antibody (D9-7/9/76, HP/D/9 - IVA, 
Guildhay Antisera) was used throughout the whole study. Normal 
rabbit serum (NRS) diluted in the same buffer was added in the 
assay tubes just before the addition of double antibody.
Dried Staphylococcus aureus, rich in pro tein A for separation 
125of antibody-bound I-glucagon, was also tried in the system. 
Protein-A, a major cell wall component of most strains of 
Staphylococcus aureus, has very high affinity (1 2 x 10 1/mole) 
for certain classes of immunoglobulins (L36) (L37). It binds to 
IgG rapidly, usually within seconds, and these properties have
already led to multiple uses of protein A in immunology including 
its use in several established radioimmunoassay systems (138) (139) .
The Cowan I strain of Staphylococcus aureus was used in 
this study. Organisms were grown over 48 hr in nutrient agar 
plates. Bacteria were harvested by centrifugation at 5000 x g 
for 20 min, washed twice in 0 .0 1M phosphate-buffered saline, 
pH 7.5 resuspended in ten volumes of the same buffer and placed
1
in a boiling waterbath for 20 min. They were then removed,
cooled down rapidly and 0.25% Formalin was added. The bacteria
were then washed twice with 0 .01M phosphate-buffered saline,
pH 7.5 and diluted with the same buffer to approximately 10% (v/v)
suspension of organisms * Sodium azide (0.1%) was added and the
suspension was stored at 4°C until use. For the assay, 150 yl
of this 10% suspension of formaldehyde - and heat-treated bacteria
were added at the end of the incubation period in each tube. After
6 hr incubation at 4°C the assay tubes were centrifuged at 2,500
rpm for 30 min and the supernatant was aspirated. The
125precipitated antibody - I-glucagon complex - w a s  counted on 
a gamma counter.
The above-mentioned separation methods were also compared 
with a charcoal separation method. The charcoal suspension was 
prepared by mixing 5 g of charcoal (Norit 65X, Hopkin and 
Williams, Chadwell Heath, Essex, UK) and 0-5 g Dextran T-250 
(Pharmacia (GB) Ltd.) with 500 ml of the assay buffer to form a 
stock solution which should be made at least 24 hours before use. 
For use in the assay, this suspension was diluted 1:4 (v/v) 
with the assay buffer to give a final concentration of 0.25% (w/v)
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charcoal. One volume of horse serum (Wellcome No.5, inactivated, 
Wellcome Reagents Ltd., Beckenham, Kent, UK) was then added to 
9 volumes of diluted charcoal slurry and the ice-cooled mixture 
stirred on a magnetic stirrer during addition to the assay tubes. 
After the addition, the tubes were left to stand at 4°C for 10 
minutes before being centrifuged for 30 minutes at 2,500 rpm in 
a refrigerated centrifuge (4°C). The supernatant was decanted 
with care and the charcoal pellets were counted.
In order to optimise the incubation periods for the assay 
and to produce maximum assay sensitivity, the association reaction 
time was examined first. Dissociation reaction time studies were 
carried out by incubating several sets of zero, non-specific 
binding and total tubes for the optimum association time and then 
adding (a) charcoal, or (b) large excess of unlabelled glucagon 
(140). Each set was then separated at different times starting 
immediately after the addition of the charcoal or excess of 
antigen up to 48 hours. From the results obtained from this study 
one could be able to judge if the assay would be better to be a 
sequential assay (later addition of label) or an equilibrium 
assay (addition of all reactants at the same time).
^25ikody_sgecificity
The specificity of the antiserum was studied by checking 
the cross-reactivity of VIP (Karolinska Institute, Stockholm) ,
GIP (Dr. J. Brown, University of British Columbia, Vancouver, 
Canada), secretin (Karolinska Institute, Stockholm) and gastrin 
(Medical Research Council, National Institute for Biological
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Standards and Controls, London, UK) in the system, as it is 
known that there are extensive similarities in the amino acid 
sequences of these gut peptides with that of glucagon.
Further studies on the specificity of the antiserum were 
done using a gut glucagon-like immunoreactant material whiGh was 
obtained from The Queen's University of Belfast, Northern Ireland, 
through Dr. J.M. Conlon. This material has a molecular weight of
f
about 1 2 ,0 0 0 , has been isolated from porcine colon and freeze-dried 
on human albumin, and was estimated by the supplier, to contain 
50 ng equivalent of GLl/mg of the freeze-dried powder as measured 
by one of their antisera known to cross-react with the N-terminal 
portion of glucagon.
Cross-reactivity with glucagon fragment sequence (1-12) and 
sequence (18-29) provided by Dr. W.W. Bromer, Eli Lilly Co. was 
also tested.
The behaviour of porcine gut GLI-I, also designated glicentin, 
purchased from Novo Research Institute (Copenhagen, Denmark) was 
also examined in the system. Glicentin, a highly purified protein 
with glucagon-like immunoreactivity from pork intestine shows only 
one band when analysed by polyacrylamide gel electrophoresis at 
pH 4.5, and by isoelectric focusing. According to the supplier, 
the concentration of glicentin provided was 0.7 5 yg/ml equivalent 
of pancreatic pork glucagon, as determined with one of their N- 
terminal cross-reacting anti-pork glucagon rabbit serum (K 402 3)- 
A range of dilutions (48-25,000 pg/ml'equiv. pancreatic glucagon) 
of this original concentration was tested in the assay.
2.2.3 RESULTS 
Iodination
125Different I-glucagon preparations obtained by the
"Iodogen method" iodination were incubated with excess of
antibody in order to test their immunoreactivity. The conditions
which yield the highest affinity tracer were the following;
125amount of iodogen used 5 yg, amount of I 5 yl (0.5 mCi) and
reaction time interval 10 min. However, compared with the 
125I-glucagon obtained by the chloramme-T method under the 
same assay conditions, the quality of this label was inferior, 
as was resulting in less maximum binding in the presence of 
excess of antibody and in less displacement of binding in the 
presence of unlabelled glucagon (Fig.2.2.1).
Antiserum titre
An antibody dilution curve at 4°C was done (Fig.2.2.2) 
by incubating[a;constantamount of label with double diluting 
concentrations of antiserum. The range and magnitude of "bound" 
fraction in the absence of unlabelled glucagon was measured and 
the concentration of antibody that gives about 40% binding of 
the label was found to be a dilution of the antiserum 1 :2 0 0 0 .
Incubation time
The association reaction time at 4°C was studied and the 
results are shown in Fig.2.2.3. It seems that after 48 hr 
incubation, the reaction almost comes to equilibrium.
The dissociation reaction studies are shown in Fig.2.2.4. 
After 48 hr incubation with charcoal or excess of glucagon, the
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dissociation amounts to approximately 30% of the originally 
bound glucagon. It could be predicted from the above data 
that the use of the sequential saturation principle in this 
assay would be advantageous, giving more sensitive standard 
curves (140) as shown in Fig. 2.2.5.
Preparation of "glucagon-like immunoreactivity free plasma"
Fig.2.2.6 shows the behaviour of the three different 
preparations of "glucagon-like immunoreactivity free plasma" in 
a standard curve in which a double antibody was used as a 
separation system. As it can be seen on the graph, heat 
inactivation at 37°C for 1 hr failed to destroy all glucagon­
like immunoreactivity in the pooled human plasma and that fact 
would account for the flat shape of the upper part of the curve. 
Inactivated charcoal-stripped plasma (second preparation) seems 
to have removed most of the immunoreactivity from the plasma, 
giving almost comparable standard curve to that constructed by 
using plasma inactivated through a specific glucagon-like 
immunoreactivity immunoabsorbent (first preparation) . For 
further use in the assay the second preparation of "glucagon­
like immunoreactivity free plasma" was chosen.
Separation system
The concentration of the double antibody as well as that 
of the normal rabbit serum (NRS) was optimised. The series 
of concentrations of double antibody that was used in this 
optimisation study was a dilution of neat double antibody 1:3, 
1:5, 1:10, 1:12, 1:15 and 1:20 and that of NRS was 1:50, 1:100, 
1:150, 1:200, 1:250, 1:400 and 1:600. The results of this study
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are shown in Fig. 2.2.7. From the graphs drawn, it is concluded 
that the optimum double antibody concentration should be an 
initial dilution of the donkey anti-rabbit IgG serum tested 1:10, 
while the NRS should be. added at an initial dilution of 1:150.
A comparison of the three different separation systems 
tested in the assay is shown in Fig.2.2.8 . Double antibody 
and Staphylococcal protein A gave almost superimposable standard 
curves whereas charcoal separation system failed to discriminate 
the first five lower standard concentrations. Also, the replicate 
in the first two methods were always better than the replicates 
obtained by charcoal separation.
Standard curve
By using the dilution of the antiserum that was giving 
about 40% binding of the label, i.e. initial dilution of 1:2000, 
the optimum concentrations of second antibody and NRS, and 
applying a pre-incubation period of 48 hours followed by an 
incubation period with the labelled glucagon of 24 hours, the 
standard curve obtained was that of Fig.2.2.9.
Antibody specificity
As it is shown in Fig.2.2.10 no significant cross-reactivity 
was found with VIP, GIP, secretin or gastrin.
The results of the study with the gut glucagon-like 
immunoreactant material isolated from porcine conlon are presented 
in Fig.2.2.11 and they show that a drop in binding from 40% to 30%
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achieved with 625 pg/ml pancreatic glucagon was reproduced with 
more than 1000 pg/ml of gut GLI. In the same figure (Fig.2.2.11) 
no cross-reactivity is shown with glucagon fragments, sequence 
(1-12) and (18-29).
[As would be expected, glicentin cross-reacted to a 
large extent in the assay as shown in Fig.2.2.12 but the antibody 
affinity for it, was markedly less than for pancreatic glucagon 
judged indirectly, comparing the cross-reactivity reported by the 
suppliers in their assay employing K4023 antiserum, an N-terminal 
cross-reacting glucagon antiserum. So, a concentration of 
glicentin assessed by the suppliers to contain 12,500 pg/ml 
equivalent of pancreatic glucagon gave as much displacement of 
iodinated glucagon as 1480 pg/ml of pancreatic glucagon, suggesting 
an eight times smaller affinity of our antiserum for glicentin 
than for pancreatic glucagon, always in comparison with antiserum 
K4023.
Sensitivity
The sensitivity of the assay defined in terms of the slope 
of the dose response curve, i.e. the change in the response 
metameter for a given change in the "dose" (2 standard deviations) 
is equal to 78 pg/ml.
Equilibrium constant, K value and Scatchard plot
The binding capacity of the antiserum and the equilibrium 
constant of antibody-unlabelled glucagon were determined by 
drawing the Scatchard plot (141) which was first introduced for 
small molecule-protein interactions and was applied to radio-
65
0
0
20 -
10 -
r
19
-• Glucagon 
o  Glicentin
Glicentin (equiv. pg/ml)
48
~l 
39 78
95
I
190 390 780 1560 3130 6250 12500 25000
1 I i l \ l ! L1 — ,--- 1 1 
156 313 625 1250 2500
Glucagon (pg/ml)
Fig.2.2.12
Cross-reactivity of the antiserum with glicentin.
immunoassay by Berson and Yalow (142) (143). The assumption that was
made is that the iodinated glucagon and the unlabelled glucagon have 
the same physical-chemical properties (apart from the presence of 
the label on the former). As a prerequisite of the drawing of a 
Scatchard plot is the estimation of the specific activity of the 
label; this was done according to Walker (L4 4) by setting up zero tube
and increasing amounts of label. In the case examined, the mass of
labelled glucagon added to each tube was found to be 12 pg and the
specific activity estimated to about 420 pCi/pg. '
The calculated value for the equilibrium constant from the
-9Scatchard plot was 5.5 x 10 1/mol (Fig.2.2.13).
Precision and reproducibility
A quality control scheme was established for.this assay. A 
pool of plasma with high level of gut glucagon-like immunoreactants 
obtained by bleeding healthy volunteers after carbohydrate meal was 
used as the high level quality control. Diluting this pool with 
pooled human plasma the low level quality control was obtained. The
results of this quality control scheme are shown in Fig.2.2.14. The
intra- and interassay reproducibility expressed as a coefficient of 
variation for the two quality control pools (high and low level pool)
was 4.6% (n = 10) and 18.59% (n = 13) respectively.
Mean value and normal range
The mean value for basal condition in normal fasting 
volunteers lies between 280 and 340 pg/ml with the range from 
160 to 410 pg/ml (n = 23).
Assay protocol
The assay protocol is shown in Fig.2.2.15.
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Assay No. Low level Q.C. pg/ml
High level Q.C. 
pg/ml
1 309 705
2 440 835
3 283 612
4 365 787
5 411 858
6 204 633
7 320 581
8 397 727
Mean 341 717
SD 77.46 103.87
SEM 27.38 36.72
cv 22.71% 14.48%
Fig.2.2.14
Results of the quality control scheme.
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2.2.4 DISCUSSION
The levels of GLI measured by this assay are reported as 
equivalents of pancreatic glucagon, as standards of pancreatic 
glucagon were employed in the assay. Furthermore, the levels 
of gut glucagon-like immunoreactivity in plasma are semiquantitative 
considering that the magnitude of changes observed under experimental 
conditions depends on the extent the antiserum cross-reacts with the 
different fractions that constitute the gut glucagon-like immuno- 
reactants.
Bloom and colleagues CL18) have reported an immunoassay 
technique for measuring enteroglucagon. The antiserum raised to 
pancreatic glucagon cross-reacted fully with enteroglucagon.
Human ileum was extracted by the method of Kenny (145) and further 
purified to provide "enteroglucagon" standards. The activity
-15
of these enteroglucagon standards in femtomole (10 mole) per 
millilitre was obtained by reference to pancreatic glucagon 
standards. This was done by assaying both standards with a 
cross-reacting human enteroglucagon antibody and enteroglucagon 
label (L21) . Although this methodology is undoubtedly very 
promising, the use of enteroglucagon standards so far has been 
restricted to one author's laboratory and thus is open to 
question until the nature of this material has been more 
precisely elucidated. ~
The limitations of the immunoassay for gut GLI do not 
seriously interfere with the use of the assay for estimating 
variations in plasma gut GLI. The variations in the values 
obtained by different techniques are still a problem, but the
effects of the choice of the antiserum are minimised, since the 
values recorded during an experiment are usually obtained in a 
single immunoassay run and are referable to a suitable pre-test 
datum point. It is uncertain if the relationship between 
different concentrations is strictly correct, ,but the immuno­
assays used are adequate to detect change in the levels of gut 
GLI. i
The discovery by Moody et: al. of a second immunodeterminant 
on the molecule of glicentin, which lies outside glicentin’s 
glucagon-like antigenic site, seems to be very promising of a 
future immunoassay that would detect only extrapancreatic 
glucagon-like immunoreactivity without any interference from 
pancreatic glucagon or proglucagon fragment, though as one could 
conclude from Fig.2.3, the small gut GLIs which, according to 
the same group constitute about 25% of the majority of gut GLIs, 
wou^d not be detected as they miss this particular imrauno- 
determinant. From the same figure it is deduced that glucagon 
N-terminal antisera would give a better, rough estimation of 
the total glucagon-like immunoreactivity as the immunodeterminant 
is present in all the peptides isolated so far and proved to show 
glucagon-like immunoreactivity.
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CHAPTER 3
EFFECT OF GUAR ADDITION IN MEALS ON PANCREATIC 
GLUCAGON AND GLUCAGON-LIKE IMMUNOREACTIVITY
3.1 Introduction
Diabetes was one of the first diseases to be classed as 
a fibre deficiency disorder (146) . A high content of many 
different unabsorbable plant polysaccharides that were found 
in the diet of non-industrial societies, where diabetes is 
uncommon (L47) , led to this classification.
f
Recently interest has grown in guar gum, which is a 
galactomannan, the storage polysaccharide of the Indian 
cluster bean (148) as an aid in the treatment of diabetes.a*
Jenkins et_ aJL (149) showed that the addition of guar to a 
carbohydrate meal will reduce the post-prandial rise in 
glucose and insulin levels in both normal and diabetic subjects, 
thus improving the control of blood glucose in diabetics and 
possibly decreasing their insulin requirements in the long 
term.
It has been suggested that the ability of guar to reduce 
the rise in glucose and insulin after a meal is related to its 
ability to limit diffusion towards the absorptive mucosal 
surface by forming gels and viscous solutions when hydrated (150) 
and to slow gastric emptying (149) , thereby causing a delay in 
glucose absorption compared with a control meal (151).
However, the magnitude of the insulin response to oral 
glucose is modified by the secretion of several gastrointestinal 
hormones. Kiehm et: a_l (]52) speculated that alteration in 
secretion of glucagon or other hormones might have contributed 
to the improvement in glucose metabolism in their study.
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In the present work, the addition of guar to two different 
meals, a predominantly carbohydrate "meal" and a genuine mixed 
meal was studied, and particularly its effect on pancreatic 
glucagon and gut hormones, enteroglucagon and gastric inhibitory 
polypeptide (GIP), as these hormones have been shown (56) (153)
or speculated (154) to modify insulin response after carbohydrate 
meal. The results of the effect of guar addition in meals on
i
pancreatic glucagon and "total" glucagon-like immunoreactivity 
only are presented here.
3.2 Materials and Methods
1. Mixed meal
The study group consisted of 5 healthy volunteers (3 males 
and 2 females; 22.6 - 2.1 years; 99.3 - 0.5% mean ideal body 
weight) and 6 insulin-treated diabetics receiving 28 to 80 units 
of insulin per day (6 males; 40.8 - 8.1 years; 100.0 - 1.1% mean 
ideal body weight). Volunteers ate the test rueal in the monring 
after a 12-hour overnight fast. The composition of the basic 
meal is shown in Table 3.1; the fibre-supplemented meal contained, 
in addition, 10 g guar (Norgine Ltd.) incorporated into the soup 
and bread. The meals were taken in random order, one to two 
weeks apart, and were eaten over approximately35 ,min.
2. High carbohydrate meal
The study group consisted of 4 healthy male volunteers
+ +(29.3 - 3.5 years; 99.6 - 0.4) and 6 insulin-treated diabetics
(5 males and 1 female; 50.0 - 7.6 years; 102 - 1.2% mean ideal
body weight) receiving 28 to 72 units of insulin per day. The
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constituents of the basic meal are shown in Table 3.1. As
in the case of mixed meal, the fibre supplemented meal 
contained 10 g guar, incorporated into the soup and bread. 
Meals were taken in random order, after an overnight fast, 
as before.
Table 3.1 Composition 
carbohydrate test meal
of the basic mixed test meal and
J
- Mixed meal Carbohydrate meal
Soup (298 ml) Soup (298 ml)
Egg (50 g) -
Components Bread* Bread
(control 36.3 g) (control 38.0 g)
(test 66.6 g) (test 68.5 g)
Butter (7.5 g) -
Milk (100 ml) -
Total carbohydrate (g) 52.1 47.3
Total fat (g) 28.1 12.5
Total protein (g) 20.2 10.6
*The difference in weight between test and control was due to 
addition of water to the guar-supplemented bread, to make 
loaves of similar consistency.
In all four tests the diabetic subjects received their 
usual morning dose of insulin 15 minutes before the meal. 
Venous blood samples were collected basally and at 15, 30, 45, 
60, 90, 120, 150 and 180 min after the start of the meal. 
Samples for pancreatic glucagon, "total" glucagon-like immuno-
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reactivity and GIP were collected into tubes containing EDTA 
and 1000 KIE aprotinin/ral, immediately separated and stored at 
-20°C.
Plasma pancreatic glucagon was measured by radioimmuno­
assay using an antiserum (Y6 ) specific for pancreatic glucagon 
(C-terminal reacting) and did not cross-react significantly 
with crude or purified extracts of whole porcine bowels.
"Total" glucagon-like immunoreactivity was measured by 
radioimmunoassay using an antiserum directed against the N- 
terminal portion of porcine pancreatic glucagon and known to 
cross-react with extracts from porcine small intestine as 
described in Chapter 2.
Blood glucose levels were measured by a hexokinase 
method and plasma immunoreactive insulin levels by radioimmuno­
assay (155) .
The results are expressed as mean - standard error of 
the mean and compared using two-tailed Student's t-test for 
paired data.
3.3 Results
The mean blood glucose responses to the predominantly 
carbohydrate meal and the mixed meal in healthy subjects and 
diabetics are shown in Fig.3.1. Results for the diabetics are 
plotted as an increment over the fasting blood glucose values 
before insulin was given, in order to facilitate comparison 
with control subjects in whom fasting blood glucose levels were 
all very similar. Addition of guar to the meals decreased the
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post-prandial rise in blood glucose concentration in both the 
healthy and diabetic subjects. The effect was greater in the 
diabetic than in the normal subjects.
Mean plasma insulin responses in the healthy subjects 
to the two types of meal with and without added guar are shown 
in Fig.3.2. The post-prandial rise in plasma insulin after 
both types of meal was significantly decreased by'the addition 
of guar.
The glycaemia/insulinaemia relationship in healthy subjects, 
as expressed by the ratio of peak plasma insulin level over the 
corresponding blood glucose level was significantly altered by 
the addition of guar to both types of meal (mean ratio for 
control meals 6.01 - 0.85, for guar supplemented meals 4.47 - 
0.83, p 0.05).
Fig. 3.3 shove:the mean "pancreatic specific" immunoreactive 
glucagon levels in healthy subjects after eating each of the test 
meals. They remained at basal levels (166 - 16 pg/ml) for the 
first hour and rose slightly, but non-significantly, in the 
latter half of the test, coincident with the fall in blood 
glucose reaching a mean plasma level of 227 - 29 pg/ml at 
120 min. There was no significant difference between any of the 
meals.
Mean "pancreatic" glucagon levels in diabetics after 
each of the test meals are shown in Fig.3.4. Again, there 
was no significant difference in any time interval between any 
of the meals.
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"Total" plasma glucagon-like immunoreactivity rose in 
response to both types of meal, in diabetics as well as in 
healthy subjects (Fig.3.5). Although the response to meals 
supplemented with guar was generally smaller than after control 
meals, statistically significant differences were obtained only 
in the case of the predominantly carbohydrate meal eaten by 
healthy subjects in whom the incremental area under the curvei
was also significantly smaller (p <0.05) for the guar supplemented 
meal.
3.4 Discussion
This study shows that the presence of guar in both test 
meals, the predominantly carbohydrate and the mixed meal, 
reduces the post-prandial rise in blood glucose and plasma 
insulin of normals and diabetics as already reported by Jenkins 
and coworkers (149) for carbohydrate meals.
Comparing the predominantly carbohydrate meal and the 
mixed meal supplemented with guar, it was the first which 
resulted in smaller post-prandial increases in blood glucose 
and plasma insulin in normals and diabetics comparing with 
the respective basic meals.
As no significant difference was found in plasma 
pancreatic glucagon levels between control and test for both 
types of meal, it could be assumed that pancreatic glucagon 
does not play any major role in the decreased insulin response 
after any of the test meals.
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It has been found that gut glucagon-like immunoreactivity
is released both by long chain triglycerides and by glucose
(115) (156), two substances which inhibit the release of
pancreatic glucagon, resulting in an overall increase of the
"total" glucagon-like immunoreactivity. In agreement with the
above, "total" glucagon-like immunoreactivity levels rose in
normals and diabetics after the control meals, but were
/
reduced by the addition of guar, though they became statistically 
different only at 90 and 150 min after the start of the pre­
dominantly carbohydrate meal.
As with gut GLI, post-prandial secretion of GIP (157) was 
reduced by the addition of guar to both types of test meals, a 
possible mechanism for both,gut GLI and GIP, being a reduction 
in the rate of absorption of nutrients. The effect of guar on 
the rise in plasma GIP levels was more pronounced when it was 
added to the carbohydrate meal than when added to the mixed 
meal. Both GIP and gut GLI are able to stimulate insulin 
secretion in the presence of hyperglycaemia. Therefore, it 
seems probably that the diminution in the insulin response to 
the test meals by the addition of guar is, at least in part, 
due to diminished gut hormone secretion, and the alteration 
in the insulinaemia/glycaemia relationship in healthy subjects 
by addition of guar to test meals supports this view. However, 
no definite conclusions could be drawn from the results of 
this study for the role of gut glucagon-like immunoreactivity 
on the modification of insulin secretion after meals 
containing guar owing partly to big individual variations, 
which were more exaggerated in diabetics, and partly to the 
small number of normal and diabetic volunteers studied.
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Samols et_ al_ (76) were the first to postulate that gut 
GLI increases the glucose-induced insulin release from the 
pancreas. Since then, the discovery of GIP took place, which 
has been shown to be a potent stimulator of insulin release, 
in the presence of hyperglycaemia. This event, coupled with 
the lack of good evidence for the insulin-releasing activity 
of gut GLI made this postulate more ambiguous than when first
i
suggested. However, Ohneda ^t aJL (158) recently reported that 
gut GLI after purification by affinity chromatography appeared 
to stimulate insulin secretion from the canine pancreas.
Pearse et. ajL (159) speculated that the main physiological 
action of enteroglucagon (or gut GLI) is to prevent foodstuffs 
from passing too far down the intestine and that release of an 
increased amount of enteroglucagon would lead to a slowing of 
intestinal transit and an increased growth of the mucosa, with 
enhanced absorption. If, as suggested by Jenkins et al, a 
slower gastric emptying occurs after meals containing guar, 
then the results of this study seem to support the above concept, 
as lower levels of gut GLI after such meals were recorded 
compared with gut GLI levels after the basic test meals.
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CHAPTER 4
USE OF HIGH TITRE GLUCAGON ANTISERUM IN PRODUCTION 
OF EXPERIMENTAL GLUCAGON DEFICIENCY AND ITS 
PHYSIOLOGICAL IMPLICATIONS IN RATS
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4.1 Introduction
The injection of insulin antibodies has been shown by 
previous investigators to produce a marked and transient 
hyperglycaemia which is proportional in intensity and duration 
to the quantity of antibody administered (160) (161).
In the present study an attempt was made to produce an
analogous condition of glucagon deficiency by neutralising
*
the circulating endogenous glucagon as this could provide 
considerable information concerning the physiological 
importance of the hormone.
It has been established that the hyperglycaemic action 
of glucagon is due to stimulation of hepatic glycogenolysis 
(162) and hepatic gluconeogenesis (163). The net rate of both 
these processes is elevated when the blood glucose level is 
being maintained by glucose release from the liver, rather 
than from dietary sources, and under these circumstances 
glucagon deficiency would be expected to cause transient hypo- 
glycaemia.
It has already been shown (164) that the hyperglycaemic 
action of exogenous glucagon can be inhibited by preincubation 
with anti-glucagon serum. Such preincubation also blocked the 
increases in hepatic phosphorylase activity and glucose output 
produced by glucagon during perfusion of isolated rat livers.
An acute blood glucose lowering effect of glucagon anti­
serum was demonstrated in 48-hour fasted adrenalectomised 
rats (165) although no effects was observed in fed or post- 
absorptive animals (165) (166) (ie 7)
Later work by Holst et a_l (168) also reported lack of 
depression of basal blood glucose after antiserum treatment 
in fasted rats, assigning no physiological role of the 
absolute concentration of plasma glucagon in the maintenance 
of basal blood glucose in the rat.
However, recent studies of glucagon deficiency induced 
by somatostatin have suggested that basal glucagon secretion 
is at least partly responsible for maintenance of' euglycaemia, 
because the glucose lowering effect of somatostatin is 
correlated with glucagon suppression and may be reversed by 
exogenous glucagon (169) (170)(37) (171).
The variable effect of glucagon antiserum administration 
in the studies mentioned above could be the result of incomplete 
neutralisation of circulating glucagon (166). According to 
Heding (172), the glucagon antibodies when used to induce hypo- 
glucagonaemia should have a high affinity to ensure complete 
binding, and a high binding capacity, at 37°C, to avoid infusing 
excessively large volumes of antiserum.
In this study a' pool of antiglucagon serum raised in 
rabbits was used with a binding capacity, avidity and titre 
more potent than the antisera used in previous studies (165)
(166) (17 3) and similar to the characteristics of the antiserum 
used by Holst et al. The neutralising effect of this pool of 
antibodies on exogenous and endogenous glucagon, on basal 
blood glucose after fasting of two different periods of time 
and in states in which active glucagon secretion has been 
demonstrated, as after insulin induced hypoglycaemia and 
arginine stimulation,was studied.
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4.2 Materials and Methods
Selection_and_characterisation__of_glucagon_antibodi.es
Antisera to glucagon for injection were produced in half­
lop rabbits immunised with a glutaraldehyde conjugation of 
glucagon to egg albumin and emulsification in Freund's complete 
adjuvant. A pool of antiserum from rabbit Y6 obtained 18 weeks 
after primary immunisation (coded Y6PR, bleed S) ,was analysed 
for titre, avidity and binding capacity. This is a C-terminal 
reacting antiserum,that is an antiserum specific for pancreatic 
glucagon (179).
Serum from normal, non-immunised rabbits was used for 
control experiments.
2?_2i222222_2B5i^2S!i22
The glucagon antibodies used in this study were 
administered in the form of an IgG fraction prepared as followsr 
two volumes of saturated ammonium sulphate at 37°C were added 
drop by drop to one volume of anti-glucagon serum under continuous 
stirring on a magnetic stirrer. After standing overnight at 4°C 
the mixture was centrifuged for 20 min in a refrigerated centri­
fuge. Part of the supernatant was kept for detection of any 
antibodies that escaped precipitation and the rest was discarded; 
the precipitated protein was dissolved in the minimum volume of 
saline, placed in a dialysis sac and dialysed against at least 
five changes of 0.9% NaCl. It was then stored and kept frozen 
at -20°C.
90
Injection_of_antibodies
Male Wistar albino rats weighing 250-320 g were used for 
antibody injection experiments. They were kept under continuous 
anaesthesia by an initial intraperitoneal injection of a 6% 
solution of phenobarbitone sodium (Sagatal, May and Baker Ltd., 
England) of 0.4 ml, followed by additional quantities (0.05 ml) 
at the slightest signs of consciousness. The animals were 
injected through the external jugular vein which had been 
cannulated with a small polyethylene catheter.
The animals were bled from the tail vein or by cardiac 
puncture, and the blood for plasma glucagon and plasma insulin 
levels was collected into chilled heparinised tubes which also 
contained aprotinin (Novo Research Institute, Copenhagen, Denmark) 
1000 KIE/ml blood. A small aliquot of blood (50 yl) was 
immediately added to 0.5 ml of 0.33 N perchloric acia for 
glucose estimation employing a glucose oxidase method (GOD- 
PERID method, Boehringer Mannheim GmbH, West Germany). .
peterminati2 n_2 f_glasma_glucag2n_and_plasma_insulin_levels
Plasma glucagon levels were measured by radioimmunoassay 
using an antiserum directed against a part of the C-terminal 
sequence of the glucagon molecule and does not cross-react to 
a considerable degree with any of the gut glucagon.
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Plasma insulin levels were determined by a double antibody 
radioimmunoassay with a detection limit of 2.5 mU/1 and intra— 
and interassay coefficients of variation 4 and 9.5 % respectively.
Standards were human insulin (Wellcome Reagents Ltd.) but 
the antiserum used cross-reacts with rat insulin, and dilution
curves of rat plasma paralleled roughly the standard curves.
;
M22£E2™22t i22_2f_J:k2_2f;!:22t:2_2f_2*2222222._2:!:222222.J23L.2:!:222222
antiserum
Three groups of 5 fed rats each were treated as follows: 
group a was injected with non-immune antiserum in the form of 
IgG fraction and 10 min later with 5 yg glucagon dissolved in 
0.5 ml of 0.9%NaCl; group b was injected with anti-glucagon 
IgG and 10 min later with 5 yg glucagon; and group c was injected 
with saline and 10 min later with the same amount of glucagon 
antibodies administered in group b but pre-incubated with 5 yg 
of glucagon for 15 min at 37°C in a water bath.
Neutralisati2n_2f_end22§B2H2_2i222222_i2_^2§tiB2_§i252
Six rats were fasted for 16 h before they were given 
the glucagon antibodies and another 6 rats were fasted for 
24 h prior to administration.
Rate_2 f _disappearance_2 f _2 i2 2 2 2 2 2_2 2 ii^2^i2 2_ ^ 2™_2 2E2I?
This was calculated by expressing the concentration of 
glucagon antibodies at 15, 30, 45, 60, 90, 120 and 150 min as 
percentage of serum antibody concentration at 5 min after 
administration of anti-glucagon IgG.
Insulin-induced_hypoglycaemia_study
Overnight fasted rats were divided into 2 groups; the 
control group (n = 5) was injected with 0.5 ml of saline and 
10 min later was given insulin (BP 20 IU/ml, Weddel Pharmac­
euticals Ltd.) 0.6 IU/kg body weight; the test group (n = 5) 
was injected with 0.5 ml of anti-glucagon IgG followed by the 
same dose of insulin intravenously as in the control group.
i
Because it was found that the nadir or glucoses in the 
control group was occurring later than expected (90 min after 
the insulin injection), when a large proportion of antibodies 
administered at "zero time" could have already disappeared 
from the circulation, it was decided to inject another group 
of 4 rats with the same dose of insulin at "zero time" but 
the glucagon antibodies were not administered until 70 min 
after the insulin injection.
In this experiment a combined use of phenoxybenzamine 
(Dibenyline, Smith Kline and French Laboratories Ltd., Herts, 
UK) and propranolol (Inderal, ICI Ltd., Cheshire, UK) was 
made to achieve a double adrenergic blockade, if possible, and 
study its effects on the restoration of blood glucose levels 
to normal after insulin-induced hypoglycaemia. The doses were
the same and the experimental design a slight modification of 
that followed by Cowell and Hetenyi (17,5) .
Phenoxybenzamine, the a-blocking agent,was injected 
intravenously over 3 min in 5 rats, 15 min prior to the 
beginning of the experiment, in a dose of 20 mg/kg body weight 
diluted in 0.2 ml of 0.9% NaCl.
93
Propranolol, the b-blocking agent was injected at a 
dose of 2 mg/kg body weight diluted in 0.9% NaCl (volume 
injected 50 yl) 60 min before the insulin administration (at 
t = -60 min) as propranolol has been found to cause some 
hyperglycaemia which, however, is transient and subsides 
within 1 hr even when a constant infusion of the drug is being 
maintained (175). This injection of propranolol was followed 
15 min later (i.e. at t = -45 min) by the initiation of a 
constant infusion of propranolol using a syringe pump (Sage 
Instruments, Orion, Model 341) at a rate of 1 mg/kg body 
weight/min (total volume injected 4 ml) which has been maintained 
throughout the entire length of the experiment. In this way 
major differences in the initial (pre-insulin) values of 
plasma glucose level between control experiments and the 
experiments with adrenergic blockade were avoided, permitting 
therefore the comparison of the "normal" responses with those 
observed under the effect of blockade.
Eleven overnight fasted rats were divided into 3 groups; 
the first group consisted of 4 rats (group a), was injected 
with 0.5 ml of non-immune serum and 10 min later was infused 
with L-arginine (BDH Chemicals> Dorset, UK) through an 
indwelling jugular vein cannula over a period of 25 minutes.
The dose of arginine used was 0.45 g/kg body weight dissolved 
in 0.9% NaCl containing 3% Dextran T70 (Pharmacia, Sweden)
(total volume infused 12 ml). The second group,consisted of 
4 rats (group b), was injected with 0.5 ml of anti-glucagon
IgG and 10 min later (i.e. at "zero time") infused with the 
same dose of L-arginine using a syringe pump as in group a.
Another 3 rats (group c) were given 0.5 ml of non-immune 
serum and 10 min later were infused over the same period of 
time used in groups a and b (25 minutes) with 0.9% NaCl 
containing 3% Dextran T70.
+The results are expressed as mean - standard error of
t
the mean and significance calculated by Student's t test for 
unpaired data.
4.3 Results
T?22_2 :!:2 2 2 2 2 2 _2B*:ik2^ 2 s_E2 2i
The titre of the pool (i.e. the dilution of the antiserum
125that bound approximately 50% of 15pg I-glucagon under
standard assay conditions (see Chapter 1) was 1:180,000.
This dilution of antiserum was incubated with increasing amounts
125of unlabelled glucagon and 15 pg I-glucagon in .a volume of 
0.45 ml and free and bound hormone separated by double antibody 
separation. The addition of 70 pg/ml glucagon significantly 
lowered the binding of the label (6% of the zero binding, 
p <0.005).
From the binding data, a Scatchard plot (Fig.4.1) was 
constructed, the non-linear shape of which indicated the 
presence of two classes of glucagon binding sites. The 
higher affinity class of antibodies was found to have an 
equilibrium constant of 2.9 x lO’*'0 litres/mol and a binding 
capacity of 6030 nmol/1. The lower affinity class of antibodies
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9had an equilibrium constant of 3.7 x 10 litres/mol and a 
binding capacity of 20.16 mmol/1 .
2222Y2EY_2£_2^22222B_225ikodies_in_the_igG_pre£aration
The glucagon antibodies recovered in the ammonium sulphate 
precipitated y-glokuli11 were assessed by constructing antiserum 
dilution and displacement curves. These curves were found to 
be almost superimposable with those obtained for the neat anti­
serum (Fig.4.2 and 4.3) indicating complete recovery of glucagon 
antibodies in the IgG preparation. Moreover, incubation of
serial dilutions of the supernatant obtained after the anmonium
125sulphate precipitation with I-glucagon did not show any 
detectable antibodies and simply paralleled dilutions of the 
supernatant obtained from similarly precipitated non-immune 
serum.
No immunoreactive insulin could be detected in the IgG 
fraction prepared from the glucagon antibodies pool and no 
antibodies to insulin could be traced.
^225Y2ii225i22_2£_552_2f 52252_25_222222222_2i222222_kY_2:!:222222 
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Fig.4.4 shows that glucagon administration in fed rats 
(group a) caused a large increase in blood glucose levels 
which reached to a peak at 40 min time after the injection and 
stayed above the basal level throughout the 60 min time course 
during which they were monitored.
When glucagon antibodies had been infused 10 min before 
the glucagon administration (group b), glucose levels rose
50
H
in
(M
• 1 1 1 1  1 1 1 1 1  - t i
2 5 0  5 0 0  1000 2 0 0 0  <1000 8 0 0 0  18000 3 2 0 0 0  6 4 0 0 0 1 2 8 0 0 0  2 5 6 0 0 0
Dilution of antiserum
Fig.4.2
Antiserum dilution curves of glucagon antibodies in neat
antiserum (•---•) and its respective ammonium sulphate
precipitated IgG preparation (o— -o) . Results are mean ± 
SEM of 6 replicates.
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Fig.4.3
Standard curves constructed using the same dilution (1:180.000)
of neat glucagon antiserum (o ») and its respective anti-
glucagon IgG preparation (0 o) . Results are mean ± SEM of
6 replicates.
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6030 40 502010•5 0
Time (min) before or after glucagon injection
Fig .4.4
Neutralisation of the effect of exogenous glucagon on blood
glucose levels. Rats in group a (o o) received nonimnune
antisarum and 10 mi;i later 5 pg glucagon; rats in group b
(©--- ») received anti-glucagon antibodies and lO min later
5 .yg glucagon; and group c (O ©) was injected with saline
and 10 min later with the same amount of glucagon antibodies 
preincubated with 5 pg of glucagon. Results are the mean - 
SEM of 5 animals in each group. Statistical significant 
difference calculated betv/een groups a and b
* = p <0.005 *
** = p <0 .0 2
*** = p <0 . 0 1
= p <0 . 0 0 1
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above the basal level and stayed there until the end of the 
experiment but they were significantly different from the 
glucose levels in group a from 10 min up to 55 min after 
the glucagon administration.
Injection of glucagon antibodies incubated with the 
same amount of glucagon administered in groups a and b for 
15 min at 37°C in group c resulted in no increase, in blood 
glucose values above the basal level at any time during the 
first 50 min. The small increase that was noted at 55 and 
60 min time after the injection of the mixture was not 
significantly different from the pre-injection level.
Tlae_effects_oflTJi.oagori_a.rit±tood.i_es_ori_toloo^_glvaoose_in. f^sted_rats
Blood glucose levels were measured in the two groups of 
rats, the 18 hr and 24 hr fasted, over a period of 150 min.
As it is shown in Fig.4.5 no significant change in blood glucose 
levels occurred on either of these two groups. A slight.but 
consistent drop which was noted between 20 and 80 min after the 
glucagon antibodies infusion in the group of 24 hr fasted rats 
never became significantly different from the pre-infusion level. 
Table 4.1 indicates that plasma insulin levels did not change 
significantly from the basal level over the period of 150 min.
Fig.4 .6 shows the disappearance rate of glucagon antibodies from 
the serum of the 24 hr fasted rats. The apparent concentration 
of unneutralised antibody in the serum decreased by 37% between 
5 min and 150 min after injection but at the end of the 
experiment more than 60% of the administered antibodies were 
still present in the circulating serum.
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Fig.4.5
Effect of neutralisation of endogenous glucagon on blood 
glucose levels.
-•rats fasted for 24 h
O o rats fasted for 16 h
Results are mean ± SEM of 6 animals in each group
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Disappearance rate of glucagon antibodies from the 
serum of 24 h fasted rats
•--- ® disappearance rate calculated as percentage of 5 min
serum glucagon antibody concentration
o o disappearance rate calculated as reciprocal of titre
of serum glucagon antibodies.
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The plasma glucagon levels measured at the beginning 
of the experiment just before the glucagon antibodies injection 
were found to be for the 18 hr fasted rats, 111.6 - 26 SEM 
pg/ml with a range from 36 to 187 pg/ml and for the 24 hr 
fasted rats 126.6 - 23 SEM pg/ml with a range from 69 to 
194 pg/ml.
The effects_of glucagon_antibodies_in_the_insulin-induced 
hypoglycaemia
Fig.4.7 shows the blood glucose pattern obtained after 
insulin-induced hypoglycaemia in rats treated with or without 
glucagon antibodies. The nadir of glucoses in the control 
group occurred at 90 min time after insulin injection and 
they were almost restored to the basal level at 180 min. The 
maximum drop of blood glucose levels at 90 min averaged just over 
2 mmol/1. As mentioned above, the test group consisted of 5 rats 
given the glucagon antibodies, 10 min before the insulin-admin­
istration or 70 min after the insulin injection. Because no 
major differences were found between the two sub-groups of rats, 
the blood glucose values obtained were summed up and their mean 
and SEM is presented in Fig.4.7. The glucagon antibodies 
failed to slow down the recovery from hypoglycaemia caused by 
the injection ofthe test dose of insulin. It is noteworthy 
that neither the level of the minimal glucose concentration 
nor the ascending slope of the glucose pattern differed at any 
time interval from those observed in the control group.
Fig.4.8 presents the glucagon levels after the insulin 
injection in the control group. Mean basal level was 87 -
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Fig.4.8
Plasma glucagon levels in rats after insulin-induced 
hypoglycaemia.
Results are mean ± SEM of 6 animals.
10000
1000
100
10- -
160 180140120100806040200
Fig.4.9 time (min) before or after injection
Semilogarithmic plot of plasma insulin levels in rats 
after injection of 0.6 I.V. insulin per kg body weight
Results are mean ± SEM of 6 animals.
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13 pg/ml at O time and started increasing gradually after 
20 min from insulin injection reaching a peak increase at 
90 min of 514 - 31 pg/ml. This peak coincides with the 
nadir or glucoses in both the control group and glucagon 
antibodies treated group. Thereafter plasma glucagon levels 
decreased almost linearly but they were found 2.5-fold higher 
than the basal levels at the end of the experiment (170 min 
after insulin injection).
The profile of the plasma insulin levels in the rats 
of the control group is shown in Fig.4.9. Five min after 
intravenous insulin,injection, the mean plasma insulin level 
exceeded 3.5 U/l. In the interval 10-40 min after insulin, 
a semilogarithmic plot of insulin concentrations showed a 
linear, time-dependent decrease. At 90 min time insulin 
levels had almost returned to basal levels. At the blood 
glucose nadir (90 min after insulin), plasma insulin levels 
were 12.6 - 6 mU/1 and plasma glucagon levels at their peak,
514 - 31 pg/ml.
The effect_of_double_blockade_in_the_insulin-induced_hypoglycaemia
In Fig.4.7 the effect of double adrenergic blockade in 
the restoration of blood glucose to the normal after the 
insulin-induced hypoglycaemia is also shown. With the 
experimental design used, double blockade had only slight effect 
on basal values of blood glucose levels. Mean blood glucose 
value in the rats with double blockade was found to be 0.25 
mmol/1 higher than that of the control group at 0 time. As 
it can be seen in Fig.4.7 double blockade significantly slowed
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down the recovery from the hypoglycaemia caused by the injection 
of the test dose of insulin.
At the end of the experiment (180 min) the blood glucose 
value was lower than the mean value of both control and glucagon 
antibody-treated groups, and averaged only 77% of the blood 
glucose value in the control group.
Arginine infusion stimulated glucagon secretion in group a 
(Fig.4.10) so that plasma glucagon levels rose within 5 minutes 
to 175% of baseline and peaked at 20 min when they reached a mean 
value of 440 pg/ml (340% above baseline).
As shown in Fig.4.11 blood glucose levels in group a rose 
immediately after the initiation of arginine infusion and apart 
from a drop at 15 min, stayed at comparable levels until 15 min 
from the end of the experiment when they started declining.
Group b responded with a slight rise in blood glucose level 
5 min after the beginning of infusion. Most of the time that 
the experiment lasted mean glucose values in this group remained 
lower than in group a, although they did not become significantly 
different at any time interval, and very close to those of group c.
Fig.4.12 shows that there was a significant increase in 
plasma insulin levels just 5 min after the start of arginine 
infusion which reached a peak at 20 min achieving almost a 12- 
fold increase. Insulin fell quickly to basal levels where it 
stayed until the end of the experiment. Group b showed only a 
slight increase in insulin levels after the start of the infusion
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Plasma glucagon levels after arginine (group a) or saline infusion 
(group c). Both groups of rats injected with nonimmune IgG 10 min 
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Fig.4.12
Plasma insulin levels after infusion of arginine (groups a and b)
or saline infusion (group c) . Group a (a •) was injected with
nonimmune IgG, group b (O-— O) with antiglucagon IgG and group c
(©-- ©) with nonimmune IgG 10 min before the start of the infusion
Statistical significance calculated between group a and b.
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Fig.4.11
Blood glucose levels after infusion of arginine (groups a and b) 
or saline infusion (group c) . Group a («— — *) was injected with
nonimmune IgG, group b (O o) with antiglucagon IgG and group c
(o 0) with nonimmune IgG 10 min before the start of the infusion.
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and they were significantly different from those in group a 
at 5 min (p<0.05), 10 min (p<0.01) and 20 min (p<0.0l).
4.4 Discussion
The aim of this study was to examine the effect of 
neutralising the endogenous glucagon on the basal concentrations 
of glucose in blood and on situations where active glucagon 
secretion occurs as after insulin-induced hypoglybaemia and 
arginine stimulation.
As the variable effect of glucagon antibodies administration 
in previous studies could be the result of incomplete neutralisation 
of circulating glucagon, an attempt to demonstrate by immunochemical 
methods if the administration of potent glucagon antisera to rats 
will lead to an extensive neutralisation of endogenously produced 
glucagon was considered to be necessary.
Whether the administration of glucagon antibodies can be 
used for the experimental production of glucagon deficiency was 
assessed by the extent of the neutralisation of endogenous 
glucagon that the antibodies were capable of achieving, and it 
would be expected that the effect of this neutralisation on blood 
glucose level would be more evident in situations where endogenous 
glucagon production is high, as in hypoglycaemia and after 
arginine, than in situations where endogenous glucagon production 
is relatively low, as in fasting states.
indications that an extensive binding and neutralisation 
of endogenously produced glucagon occurred after the administration 
of antibodies were as follows: The binding capacity and avidity
of the dose of antibodies injected in all experiments done 
calculated from the Scatchard plot appears to be adequate. The 
total binding capacity of the antibodies used, calculated as 
the sum of both binding sites capacity was about 13 nmol which 
is capable to neutralise 12 times the total content of glucagon 
in the rat pancreas, estimated by Barling et al (166) to be
1.08 nmol. Even if only the high affinity, low capacity class
of antibodies is taken into account, the capacity calculated toi
3 nmol per rat is three times larger than the total content of 
rat pancreas and considerably larger (almost 90 times) than the 
total glucagon production over 60 min of the moderately
stimulated rat pancreas quoted to be 0.032-0.052 nmol/h (176).
Also, the affinity for glucagon antibodies (high affinity class) 
which was calculated to be 2.9 x 10^° litres/mol is much higher 
than that reported for the hepatic glucagon receptor of the rat 
by Rodbell et: aJL (5l) (2.5 x 10 litres/mol) and Cautrecasas (177)
(4 x 10 ^ litres/mol). This would favour the binding of 
circulating glucagon to antibody rather than to the target 
organ receptor.
The effect of exogenous glucagon administered in a dose 
of 5 yg per rat (0.47 nmol/kg body weight) which in control rats 
produced significant hyperglycaemia reaching a peak of 12 mmol/1 
was masked to a large extent by the antibodies injection. This 
result is consistent with those reported by Frohman et a_l (164) 
and Holst e_t al CL68 / although in those cases the dose of 
glucagon used was considerably lower (28.5 pmol/kg in the first 
study and 30 pmol/kg in the second) than the one used in the 
present study by a factor of 150. The injection of 5 yg of 
glucagon incubated for 15 min at 37°C with the same amount of
antibodies did not result in any significant change of blood 
glucose levels from the pre-injection level suggesting that 
at least in vitro the dose of antibodies used is capable of 
complete neutralisation of the total content of glucagon in 
the rat found to be about 3.8 yg (166).
Although all of the above findings indicate that an 
extensive neutralisation of endogenously released glucagon 
will take place after the administration of a'potent antiserum, 
no hypoglycaemic effect could be demonstrated in the 18 hr 
and 24 hr fasted rats treated with antibodies. As it is well 
accepted that glucagon action is due to stimulation of hepatic 
glycogenolysis and hepatic gluconeogenesis, it might have been 
expected that maintained or increased concentrations of 
glucagon in fasted rats would be essential for the maintenance 
of basal glucose levels. The plasma glucagon concentration in 
the rats just before glucagon antibodies injection was in the 
18 hr fasted group 111 - 26 pg/ml and in 24 hr fasted 126 - 23 
pg/ml and the estimated total circulating glucagon of about
3.5 ng (1 pmol) would have been expected to be extensively 
neutralised by binding to the antibodies. That the administered 
antibodies were not completely neutralised by endogenous glucagon 
was demonstrated by their rate of disappearance in serum which 
showed that even after 2% hours there was still an excess of 
glucagon antibodies (about 70% of the antibodies circulating at 
5 min after the injection).
As the antigen-antibody reaction is reversible and obeys 
the law of mass action, we would not expect with this technique 
to neutralise all of the circulating glucagon in the rat, but
the efficiency of the technique will depend on how low the 
resulting concentration of unbound glucagon will be. It 
might be possible, therefore, that the reduction of the 
concentration of free glucagon achieved by antibodies treatment 
was too small to cause detectable signs of glucagon deficiency 
on blood glucose levels. The rate limiting factor of the 
reaction Ag + Abas=pAgAb in this case is the amount of bound 
glucagon, so that it is very difficult to lower further the 
concentration of free glucagon by increasing the amount of 
injected antiserum. To add 'to1 the difficulty of this problem 
Holst et. aJL (168) found that glucagon antiserum itself contains 
high concentrations of antibody-bound glucagon. However, one 
could argue the presence of such high concentrations of bound 
glucagon reported (up to more than 1000 nmol/1) on the basis 
that glucagon is very labile in serum when no aprotinin is 
present and in temperatures that usually antisera are kept 
(4°C). And although there are no data about the stability of 
glucagon molecule in complex with antibody, considering that 
the antigen-antibody reaction is always reversible, the time 
of exposure of glucagon molecules to proteases and other 
damaging factors, as they move from one binding site to another, 
especially during long storage of antisera, could not be left 
unaccounted. This exposure would be expected to result in an 
eventual loss of all or a large part of immunoreactive glucagon.
Another possible explanation of the lack of a physiological 
effect of glucagon antibodies is that the rate of reaction of 
glucagon with antibody was too slow for neutralisation to be 
achieved during the time taken for glucagon to pass from its 
site of secretion, the pancreas, to its target organ, the liver.
It could be argued against this that after administered 
antibodies have been equally distributed to every organ of 
the body, glucagon molecules arriving at the liver would be 
expected to get bound by the in situ antibodies than by the 
liver glucagon receptors because of their greater affinity 
for it.
A rough estimate of the speed of the reaction between
t
glucagon and antibody could be obtained by calculation from 
the kinetic curves (Fig.4.13) on the assumption that this 
reaction is first order with respect to antibody and doubles 
for every ten degrees rise in temperature. Assuming that the 
glucagon concentration in the portal vein is 3-4 times the 
peripheral levels, i.e. in our case 0.5 ng/ml, it would take 
approximately 1 sec for the glucagon antibodies to half- 
neutralise a blood glucagon concentration of 1 ng/ml at 37°C ; 
taking into account only the high affinity class of antibodies. 
This time interval is the same order of magnitude as the time 
taken for blood to arrive from the pancreas to the liver 
through the portal circulation of a rat (166) -
Thus, the lack of a physiological effect of glucagon 
antibodies in the basal fasting levels would mean either
(a) that the effects of glucagon on the liver may be readily 
compensated for by other mechanisms, as diminished insulin 
secretion 0-6^, adrenal stimulation, or (b) that glucagon is 
not that important for the maintenance of euglycaemia in the 
rat. In this study no change in insulin secretion could be 
detected in the glucagon antibody-treated rats and no increased 
adrenergic activity would be expected unless some degree of
113b
Final dilution of antiserum
o
o
00
o
CO
CO
CM
O
00
CD
CM
m
o
oo
(001 x j, ) punoq uofieoniB-i % 
/ct Stl
Fi
me
-c
ou
rs
e 
of
 
th
e 
re
ac
ti
on
 
of
 
io
di
na
te
d 
gl
uc
ag
on
 
wi
th
 
gl
uc
ag
on
 
a
n
t
i
b
o
d
i
e
s
 
(P
er
ce
nt
ag
e 
of
 
ad
de
d 
1
2
5
I~
gl
uc
ag
on
 
bo
un
d 
is
 
co
rr
ec
te
d 
fo
r 
no
n-
sp
ec
if
ic
 
bi
nd
in
g)
Ta
bl
e 
4.
2 
Ch
ar
ac
te
ri
st
ic
s 
an
d 
ef
fe
ct
 
of
 
gl
uc
ag
on
 
an
ti
se
ra
 
on
 
bl
oo
d 
gl
uc
os
e 
le
ve
ls
 
in 
ra
ts
, 
re
po
rt
ed
 
by
 
se
ve
ra
l 
w
o
r
k
e
r
s
-P -P -p
b b b b
d 0 0 0
m  -p  ^ u u O
d  -p ^ •p •H •H
u m
0  0 ft ■p ft •P = •H
Cn t o  i—1 o b O b b
b  b  0 p cn 0 p d> 0 tn 0
0  *P > d •p  cn d •p cn -P tn
rb 1 0 0  b to b u) b
CJ 0  i—1 0 0 0
P O O ,b in d  ^ O rb
ft ID 53 u CM 53 O 53 o
0
-p
0
p
m
o
0
ft
do
p
o
Tf0
to
s -H
TJ B 
0  o
■p -p 
co u 
0 0 <P i—I 
0
P b  
,b  0  
p
00 d  
^ td
d0
-P
(0
0m
p
rb
m
d  - 0
d  0 
0  *p 
-p -p 
to 0  
0 0 
m  p  
u
d
0
0
-r-J
go
-p
I
4J
u 
0 
I—I 
I—I
d
d
d  d  iP 0
0  -p d  4J
4-j u  d  00 0 0 0
0 ^  g WH 
4H 4J O d  
0  b  0  P  
P f t  0  (0 ^
rb B  P -H  
& d  B O
CM 0 0  01 0 O ' 1
b  
0 
ft ^ 0
p
rd
IH 
0 
- b
d  0 
0  p
-P d
to 0 TI 
0 0 
‘P > i  0  
i—I *H
p 0 e
r t  -P O 
d  -p  oo u v 
0 0
P
rb
CM
d  d
b  0
0  -P 
co
ID 0  tH m
•P
b  b
d  0 r t
o > B 
B *p <; cn
*
o
iP
CO
in
o
in
O
B
d  -p
,Q -p
-p  0■—I 
•H 
d  
d*
w
d d
g g
rP \
dd rP
rP
< O O
1 rP 1 *--1 rP
o O
cn 1—I rH
o X X
rP r - cn
X • - ♦
rH n CM
rP 1—1 i—i H
rP g B g g
B \ \ \ \
\ Cn Cn Cn Cntn b b b b
b
O O O bo o CM o ID
in 00 CM rP
rP 00 cn
>i
Cn-P 
b  *P 
•P 0  
d  0  
b  f t
•P 0  
CQ U
oO O oo O o
0 o Op * I i * o
■p o o 00
i—1 1—1
Eh ••H
• •
1—1
• »
rP
•—11 >10| H l d0 0| rpl d0 ■ 1 -Pi
®|?
ip
01 -pU
b
0
^tn
-blip CnJn 0^
0
-p
p 0|^ b ^ P ^ '—' b
0 •p 0 4-> 0
m >iO rP CO rQ r^ 0  00 0
0 0 r- P  r - b r- Ip r- 0p cn 0 cn d cn o cn PO rP pq «p Q 1-1 K rP p4
-H
£
g
I—I
b
*p•—i
d
■—i 
Cn 
I
0
Cn
d •
0 g4J d
0 p-p 0
•p 0
ft•p i—1
u 00 b
P -p
ft cn
•p
0 p
-P o
0
0
Oi rbi—i •P
d
0 IP
O
gd •p
■p 0
b
O -P
g
g 00 0
g
IP *rl
O -P
g bp 0
d 4->m
>1
b
-H 0
-P
0
0 gp ■r|
0 X-p d
0 p
•H ft
b ft
•H 0
g
T5 b
0 d-p
0 4-)
0 0
•P P
■d 4J
O b
rQ 0
*P o
-P b
b o
< u*
hypoglycaemia had first occurred. The role of glucagon in 
the regulation of basal blood glucose levels in fasting state 
did not prove to be major. Its essentiality in glucose homeo­
stasis could be questioned when comparing these results with 
results obtained after administration of insulin antibodies 
which is always associated with a profound disturbance of 
glucose regulation.
* *
Table 4.2 summarises the variable effects of glucagon 
antibody administration and a description of the characteristics 
of the antibodies used is being made.
Neutralisation of glucagon also failed to slow down the 
recovery from hypoglycaemia induced by insulin where active 
glucagon secretion occurs with a six-fold increase at the peak. 
The demonstration that double adrenergic-blockade did change 
the pattern of glucose levels delaying their restoration to 
the basal state is in agreement with data reported by Garber 
et al (178) according to which the first hormonal response to 
hypoglycaemia is increased catecholamine secretion and that 
increased glucagon secretion may serve only as a reinforcement 
to the mechanism responsible for the restoration. The primary 
role of catecholamine secretion in initiating the counter- 
regulatory response to insulin-induced hypoglycaemia is supported 
by the fact that it precedes or coincides with the increase of 
glucose production by the liver and evidence that enhancement 
of plasma cyclic AMP levels is mediated by catecholamines, 
while glucagon does not contribute significantly to this 
phenomenon (179). Furthermore, recent tracer studies aimed at 
evaluating the role of glucagon in insulin hypoglycaemia
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revealed that glucagon deficiency induced by somatostatin 
does not impair significantly the recovery from hypoglycaemia 
(18 0)..
The effects of glucagon antibodies on arginine 
stimulation are considered to be the more interesting. Although 
neutralisation of glucagon did not result to any significant 
change in blood glucose levels, it did significantly modulate 
insulin secretion. The insulinotropic action of glucagon 
has long been established (56) (18l) , but the capability of
glucagon antibodies to enter into the space separating A- and 
B-cells and block the secretion of A-cell has not been reported 
in the past. The implications of this finding are of great 
importance as the use of antibodies against the hormonal product 
of any cell of endocrine pancrease might prove a powerful tool 
in understanding (a) the true physiology of each cell isolated 
from its paracrine influences, and (b) the existing inter­
relationships between the cells.of endocrine pancreas.
CHAPTER 5
THE INSULINOTROPIC ACTIVITY OF ARGININE IN GLUCAGON-
IMMUNISED RABBITS
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5.1 INTRODUCTION
The insulinotropic activity of arginine has been shown in 
many species but the exact mechanism by which stimulation of 13- 
cell occurs has not as yet been resolved. The role of glucagon 
on the insulin-releasing property of arginine has not been 
assessed.
The theory put forward by Milner (182) that amino acids
t
stimulate insulin secretion indirectly by eliciting glucagon 
secretion from the A-cells has not been tested so far as no 
experimental models with complete glucagon deficiency have been 
achieved. Efforts to "kill" selectively the A-cell of pancreas 
by cobalt chloride (183) or neutral red injection (184) and 
preliminary encouraging results were not confirmed by later more 
careful and extensive studies (185 ) (186 ) .
A closer situation to this greatly desired experimental 
work could be considered experimental animals with glucagon 
antibodies present in their circulation. Assuming that these 
antibodies are of a high affinity and binding capacity, they 
should be theoretically capable of blocking A-cell secretion as 
soon as exocytosis of secretory granules of glucagon occurs before 
they "hit1 the B-cell or the currently considered target organ of 
glucagon, the liver.
In Chapter 4, the effect of neutralisation of circulating 
glucagon in rats given high titre glucagon antiserum during an 
arginine stimulation test showed an impaired response of B-cell 
and preliminary results in glucagon-immunised rabbits showed
119
that arginine failed to stimulate insulin secretion to the same 
extent that it did in control animals (174).
In this study, glucagon-immunised rabbits were used to 
assess further the effect of glucagon antibodies on the insulino- 
tropic activity of arginine.
5.2 METHODS AND MATERIALS
'White., half-lop female rabbits, weighing 4.5-5 kg, immunised 
against glucagon and normal, half-lop, female rabbits, age-matched 
to the. immunised, served as experimental animals.
The immunisation procedure was as follows: glucagon was coupled 
to egg albumin using glutaraldehyde as coupling agent. 2.5 mg 
crystalline porcine glucagon diluted in 0.5 ml of 0.1 N NaOH and 
5 mg egg albumin were dissolved in 10 ml of 0.04 M phosphate buffer 
pH 7.4. 1 ml of a 1:100 (v/v) glutaraldehyde aqueous solution was
added dropwise to the mixture with constant mixing. The resultant 
solution was emulsified with 5 ml of Freund's complete adjuvant.
3 ml of this emulsion was injected in 12 different sites in each 
rabbit subcutaneously and intramuscularly. The animals were 
boosted twice, five and seven months after the primary immunisation. 
The dose of immunogen per animal injected in each boost was half
of that used in the primary immunisation. The experiments carried 
out on the immunised rabbits were performed one and a half months 
after the last boost.
An L-arginine infusion was carried out on 4 immunised and
4 non-immunised rabbits in two different states: after an overnight 
fast and in a fed state.
30 ml of a 10%(w/v) arginine solution sterilised through a 
Millipore filter (0.22 ym, GSWP, France) corresponding to a dose 
of 0.6 g/kg body weight were infused constantly into the marginal 
vein of the left ear through an indwelling cannula (Butterfly - 
21,0.8 mm, Abbot Ltd., Ireland). The infusion lasted over a period 
of 15 minutes and the infusion rate (2 ml/min) was kept constant 
with the use of a syringe pump.
i
The rabbits were kept conscious throughout the experiment 
and were bled from the marginal vein of the right ear 10 min 
before and at 0, 5, 10, 15, 20, 30, 45 and 60 min after the start 
of the infusion.
Blood samples were collected into ice-cold heparinised plastic 
tubes containing 1000 KIE aprotinin per ml of blood. They were spun 
down immediately and the plasma was stored at -20°C until assayed.
Blood glucose, plasma insulin and glucagon levels were 
measured. A glucose-oxidase method was employed for determination 
of blood glucose and plasma insulin and glucagon were measured by 
radioimmunoassay.
+
The results are expressed as mean - standard error of the 
mean and significance calculated by Student's t test for unpaired 
data.
5.3 RESULTS
Antibody dilution curves were constructed on the sera of 
immunised animals obtained the day that the experiments were 
performed and the results are shown in Fig.5.1.
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Dilution of serum
Fig,5,l
Antibody dilution curves constructed with the sera of 
four glucagon-immunised rabbits used in this study; 
estimation of their titre.
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The titres of the antibodies in the sera of the immunised 
rabbits (i.e. dilution of the serum giving 50% of the maximum 
binding achieved with excess of antibody) were within a range of 
1/345 to ^ S O O .
Arginine _infusion__in_fasted_ state
Fig.5.2 depicts blood glucose levels in normal and glucagon 
immunised rabbits which did not move significantly, from the basal 
levels in either group.
Plasma insulin levels (Fig.5.3) stayed near the preinfusion 
levels as long as the infusion lasted and showed a small increase 
in the second half of the experiment in both groups.
A very big rise in plasma glucagon levels was found in the 
normal rabbits soon after the initiation of the arginine infusion 
which peaked at 20 min time averaging an approximately 800% increase 
(Fig.5.4).
Blood glucose levels in the normal rabbits showed an increase 
which averaged 1 mmol/1 at 5 min after the start of the infusion, 
thereafter falling gradually to preinfusion levels (Fig.5.5). In 
the glucagon-immunised rabbits, a slight drop in blood glucose 
occurred during the infusion. Comparing blood glucose levels in 
the normal and glucagon-immunised rabbits, they were significantly 
different at 10 min (p <0.01) and 15 min (p <0.01) after the start 
of the infusion.
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Fig. 5.2
Blood glucose levels in response to arginine infusion in normal
— ») and glucagon-immunised rabbits (O O) in a fasted state..
Results ;are the mean ± SEM of 4 animals.
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Time (min) before or after the start of the infusion 
Fig.5\3
Plasma insulin levels in response to arginine infusion in normal
(»- •) and glucagon-immunised rabbits (o o) in a fasted state.
Results are the mean ± SEM of 4 animals.
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Fig.5.4
Plasma glucagon in response to arginine infusion in normal 
rabbits in fasted state. Results are the mean ± SEM of 
4 animals.
*P <0.01 
**p <0.005
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Fig.5.5
Blood glucose levels in response to arginine infusion in normal
(<» - -•) and glucagon-immunised rabbits (0 O) in fed state.
Results are the mean ± SEM of 4 animals.
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Fig.5.6
Plasma insulin levels in response to arginine infusion in normal
(o ©) ana glucagon-immunised rabbits (O o) in fed state, expresse
as percentage increment over the preinfusion insulin values.
Results are the mean ± SEM of 4 animals.
Changes in insulin levels were calculated and plotted as 
percentage changes over the basal levels (Fig.5.6), as the 
insulin levels recorded before the start of the infusion were not 
comparable. A bigger increase was found in the normal rabbits 
throughout the experiment but this increase became significantly 
different from that found in the glucagon-immunised rabbits only 
at 5 min time (p <0.02). Mean plasma glucagon responses in normal 
rabbits are shown in Fig.5.7. There was a substantial rise which 
lasted for the first 30 min. However, this increase was not of 
the same order as the increase in plasma glucagon levels recorded 
in normal rabbits in fasted state (Fig.5.4).
5.4 DISCUSSION
The glucagon-immunised rabbits used in this study were 
producing sufficient antibodies to be classed in the immune group,
as could be judged from Fig.5.1. .
'Arginine failed to stimulate insulin secretion in normal
'rabbits Jin fasted state. The dependence of insulinotropic effect; 
on the glucose concentration that the B-cells are exposed to, has 
been reported in the past by several workers (187) (188) , but it
has not been explained adequately. Despite the huge increase in 
plasma glucagon, insulin levels stayed near the basal levels 
during the infusion. It has been speculated (181) that fasting, 
by reducing intra B-cell glycogen, may reduce the responsiveness 
of these cells to glucagon. Another explanation might be that 
after an overnight fast, the glycogen stores of the liver have 
been depleted and no release of glucose would occur as a result 
of glucagon's action action in the liver which would provide the 
necessary threshold of glucose for insulin release.
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Fig.5.7
Plasma glucagon levels in response to arginine infusion in 
normal rabbits in fed state. Results are the mean ± SEM 
of 4 animals.
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In the fed state, a prompt increase in insulin levels occurred 
in normal and glucagon-immunised rabbits as soon as the infusion 
started. However, mean plasma insulin levels were markedly lower 
in the glucagon-immunised rabbits throughout the infusionbut | 
were significantly different from those in normal rabbits only 
at 5 min after the initiation of the infusion due to big individual
variations. These results are in agreement with results reported
1
in Chapter 4, when arginine failed to stimulate insulin secretion 
in rats given exogenous antibodies, and give support to the hypo­
thesis proposed by Milner (182) that arginine stimulates insulin 
secretion indirectly by eliciting glucagon from the A-cells.
The mechanism by which glucagon antibodies reduce the 
insulinotropic effect of jarginine is not clear. It is possible 
that they can (a) either block the A-cell secretion as soon as 
exocytosis occurs so that glucagon does not "hit" the B-cell or
(b) block glucagon action in the liver so that the enhancement 
of insulin secretion that would normally result, from the presence 
of liver-released glucose, is abolished. A combination of the 
above two mechanisms can also be operating.
Finally, no correlation between individual insulin responses 
and individual titre of glucagon antibodies in the sera of 
glucagon-immunised rabbits could be drawn, indicating that the 
most important factor for the manifestation of the effects of 
glucagon antibodies is not their binding capacity, which is 
virtually expressed by their titre, but their affinity constant.
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CHAPTER 6
THE STIMULATION OF A AND B CELLS OF THE 
PANCREAS BY AMINO ACIDS
6.1 INTRODUCTION
6.1.1 General
In past years abundant evidence has accumulated indicating 
that hyperaminoacidaemia does, in general, exert a powerful stim­
ulatory effect upon. A- and B-cells of the pancreas. The mechanism 
of this stimulatory effect is not clear. What is clear, so far, 
is that an increase in the plasma concentration of certain amino 
acids is associated with an obligatory rise in the'plasma level of 
pancreatic glucagon (189). This response occurs at physiological 
concentrations of A-amino nitrogen, and can be induced with equal 
facility by intravenous or enteric administration of amino acids or 
protein. The teleology of the rise in glucagon secretion in 
response to protein ingestion is of particular interest and it 
became more interesting since it was reported by some workers in 
the field that is the only physiological situation in which the 
secretion of the A- and B-cells change in the same direction.
Up to now two explanations have been provided for the stim­
ulation of A-cell by amino acids. The first integrates the 
glucagon stimulation mainly in one physiological concept: prevention 
of postmeal aminogenic insulin-induced hypoglycaemia as proposed by 
Unger et a_l (190) . Maintenance of euglycaemia during aminogenic 
insulin secretion might well be explained by a carefully titrated 
increase in glucagon .secretion sufficient to replace from the 
liver, the glucose lost from the extracellular space.
The second and most recent explanation relates the amino 
acid stimulating potencies to their respective known metabolic
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fate as proposed by Rocha et aJL (L9l) , regarding glucagon as a 
potent gluconeogenetic hormone which may play a central role in 
the regulation of exogenous gluconeogenesis. This explanation 
was based on the fact that glucagon secretion is stimulated 
strongly by those amino acids which contribute the most to amino 
acid-derived gluconeogenesis, such as^  alanine and other amino aGidst 
which according to Felig (192) generate 75-90% of amino acid-
f
derived glucose. . . •
It was only lately that another explanation appeared, 
suggesting that the stimulatory effects of amino acids on B- 
and A-cells are related to a specific interaction with a receptor 
located at the level of the B- and A-cells (193), though according 
to the proposers, this receptor hypothesis would be further 
supported if D and PP cells of the pancreas responded in like 
fashion to the stimulus on B- and A-cells.
Finally, experimental work done on the stimulation of A- 
and B-cells by amino acids concludes that the rise in glucagon 
and insulin induced by the intraduodenal administration of amino 
acids seems to precede the rise in the concentration of amino 
nitrogen, the presumed stimulus of the islet cell response. This 
"anticipatory" reaction of the A- and B-cells to ingested amino 
acids contrasts with the islet cell response to intravenously 
administered amino acids in that the response precedes rather 
than follows the change in amino nitrogen concentration. This 
suggests that humoral secretions of the gut released at the start 
of amino acid absorption are involved in the response of A- and
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B-cells to amino acids (194) , and the question that arises is if 
a similar mechanism that was found for oral loads of glucose is 
operating after oral loads of amino acids, and if so, by which 
gut hormone this is mediated.
6.1.2 Amino acid-glucagon relationships
Much evidence has been accumulated in recent years to 
indicate that, indeed, hyperaminoacidaemia does, in' general, 
exert a powerful stimulatory action upon A-cells (Assan et. al,
1967 (L95) ; Fajans et. al, 1967 (196) ; Ohneda e_t al, 1968 (197) ) .
In man, studies of the effects of intravenously administered 
amino acids have almost been confined to arginine. Several groups 
have observed its powerful stimulatory effect on the secretion of 
the A-cell hormone (Assan et. aJL, 1967 095); Fajans ejt aJL, 1967 (’136); 
Unger ejt aJL, 1970 0.98)). An immediate increase in glucagon 
concentration is uniformly observed, reaching a peak at the end 
of a 40-minute infusion. Most of the rise in plasma glucagon 
occurs during the first 5 minutes of the infusion. A rise of 
at least 100 pg/ml has been observed in every normal individual 
tested thus far, and the arginine infusion test has been 
recommended as a standard test of A-cell function (Unger jet al,
1970 (198))- As first observed by Floyd and coworkers (199) the 
infusion of arginine is accompanied by a uniform increase in 
insulin and by a modest rise in glucose concentration, which 
averages 15 mg/100 ml in normal.
However, it was soon realised that big differences exist 
in the glucagon-stimulating activity of individual amino acids
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and that there is absence of parallelism between gluconeogenetic 
ability and glucagon' secreting power (Assan et al, 19 71 (230) ; Kaneto 
et al, 1971 (20l) ; Rocha et al, 1972 0-91) ; Christensen et al, 1971 
(202))* Also, the respective glucagon stimulation potencies found 
could not be paralleled with the insulin-stimulation potency and no 
other obvious relationship could be established between the magnitude 
of glucagon stimulation and one biochemical or biological character
f
(cyclic or branched structure, solubility in water, acid or base 
pHi (200)).
This led several investigators to look at the stimulation of 
A- and B-cells by different amino acids, as important information 
could be obtained by considering their glucagon-stimulating activity 
with their own biochemical and physiological characteristics.
6.1.3 Studies on tryptophan-glucagon relationships
It was first Adjukiewitz et al (233), in 1968, who studied 
the effect of oral L-tryptophan on endocrine pancreas. No significant 
insulin-releasing activity of L-tryptophan was found in the fasting 
group and the blood glucose levels did not show a consistent pattern 
in either group. However, 9 out of 14 non-fasting subjects showed 
a marked rise in plasma insulin. In this study, the failure of the 
fasting group to respond to oral tryptophan is of interest.
In 1971 Assan and Hanoune (200) studied the effects of intra- 
gastric and intraperitoneal administration of 8 amino acids on 
pancreatic glucagon and glucagon-like immunoreactivity in rats.
They showed that pancreatic glucagon rose frankly after intragastric
administration of leucine, tryptophan, tyrosine, alanine and 
arginine and the stronger stimulators were tryptophan and leucine. 
Non-pancreatic GLI in all cases decreased reaching values close to 
zero when strong stimulations were observed for pancreatic glucagon. 
Some hypoglycaemia occurred after leucine and tryptophan loads and 
hyperglycaemia was observed after other amino acids, mainly alanine, 
valine and glutamate.
f
Tryptophan was ranked seventh in order among 20 amino acids 
when Rocha et ad (191) studied their glucagon-stimulating activity 
after intravenous administration in dogs. They found that it had 
the greatest insulin-stimulating activity.
Hedo et al (204) in 1977 administered L-tryptophan orally at 
a dose of 10 g in healthy volunteers after an overnight fast. 
Tryptophan ingestion was followed by a slight rise of blood glucose 
levels and a clear elevation of plasma glucagon concentrations that 
showed statistical significance from 40th min until the end of the 
test. A small increase of insulinaemia was also detected. They 
concluded that the effect of tryptophan to elicit glucagon secretion 
in man might very likely be exerted by its direct action on the A- 
cell, since tryptophan enhances glucagon release by isolated islet 
of mouse pancreas.
6.1.4 Effect of tryptophan on A- and B-cells of pancreas
In the present study the effect of the essential amino acid, 
L-tryptophan, on the endocrine pancreas was studied in rats. 
Tryptophan was given intragastrically or intravenously and the 
effects of these two different ways of administration on blood 
glucose, plasma insulin and glucagon concentrations were examined.
It has been shown that in the recently fed individual, 
a relatively small dose of tryptophan is a potent stimulus to 
insulin secretion (203) but is a very poor stimulus when given 
intravenously. To determine whether humoral secretions of the 
gut are involved in the insulin response to amino acids, plasma 
levels of gastric inhibitory polypeptide (GIP), the current 
favoured mediator of entero-insular axis, were also measured.
t
The effect of adrenaline upon pancreatic insulin release 
provoked by intravenous tryptophan was also studied. The 
inhibitory effect of adrenaline on insulin secretion induced 
by intravenous glucose is well recognised (205) (2D6). However, 
Conway et al (237) recently reported that alanine-induced insulin 
secretion is independent of adrenaline suggesting a different 
pathway of release from the one mediating glucose stimulated 
insulin secretion.
The effect of somatostatin on A- and B-cells of the pancreas 
after tryptophan stimulation was investigated. Somatostatin was 
given before the initiation of an L-tryptophan infusion and the 
insulin and glucagon responses before and after withdrawal of 
somatostatin effect was examined.
Finally, the insulin and glucagon stimulating activity of 
two different amino acids, L-tryptophan and L-arginine, was 
studied using isomolar doses and under the same experimental 
conditions in rats.
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6.2 MATERIALS AND METHODS
Male Wistar albino rats aged 12 weeks, weighing 290-350 g* 
were used for all the experiments listed below.
6.2.1 Intragastric administration of L-tryptophan
L-tryptophan purchased from Sigma Chemical Co. (St. Louis, 
U.S.A.) was suspended in normal saline to a concentration of 
14 g/100 ml by raising the pH to 10.2 with NaOH (solubility of L- 
tryptophan in distilled water: 1.15 g/100 ml). 1.2 ml of this 
solution corresponding to a dose of 0.5 g/kg body weight was 
administered by gastric tubing to rats anaesthetised by an initial 
intraperitoneal injection of a 6% solution of phenobarbitone sodium 
(Sagatal, May and Baker Ltd., Dagenham, UK). Additional quantities 
(0.05 ml) of phenobarbitone were injected at the slightest signs of 
consciousness. A heating lamp was used to ensure normal body 
temperature throughout the experiment.
The experimental design was as follows: 30 rats, overnight 
fasted, were given L-tryptophan, 0.5 g/kg body weight, at "zero 
time". Groups of 6 rats each, were bled by heart puncture until 
exsanguination at 5, 10, 30, 45 and 60 min after administration 
and then killed. A large volume of blood (at least 6 ml) was 
obtained out of each rat.
Another 20 rats were given 1.2 ml of normal saline with pH
10.2 adjusted by addition of NaOH, and were bled until ex­
sanguination at the same time intervals (groups of 4 rats at each 
time interval) serving as controls. "Zero time" interval values 
were assessed on 6 overnight fasted rats bled the same way and 
killed before any intragastric administration had started.
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6.2.2 Intravenous administration of L-tryptophan
The same solution of L-tryptophan used in the intragastric 
study, sterilised first through a Millipore filter (0.22 ym, GSWP, 
France) was injected to overnight fasted, unconscious rats through 
a tail vein. 0.4 ml of this solution was administered as a flash 
injection, corresponding to 0.166 g/kg body weight, that is one 
third of the dose given orally.
f
The number of control and test rats used and the experimental 
design followed was the same as in the intragastric administration 
study.
A small fraction (50 yl) of the blood obtained after intra­
gastric or intravenous administration of L-tryptophan was added to 
0.5 ml of 0.33N perchloric acid and processed for glucose deter­
mination and the rest was immediately transferred to an ice-cold 
heparinised plastic tube containing 1000 KIE aprotinin (Novo 
Research Institute, Copenhagen, Denmark) per ml. The blood was 
spun down in a refrigerated at 4°C centrifuge and the plasma was 
aliquoted into small plastic vials for the determination of 
tryptophan, insulin, glucagon, "total" glucagon-like immunoreactivity
and gastric inhibitory polypeptide (GIP). They were deep-frozen at 
o-20 C until assayed.
6.2.3 Infusion of L-tryptophan
After an overnight fast (16-18 h), a constant infusion of a 
sterilised solution (1.65 g/100 ml of saline) of L-tryptophan at 
a rate of 0.5 ml/min was given in 6 rats through an indwelling 
jugular vein cannula using a syringe pump. The infusion lasted
for 25 min and the dose used was 0.5 g of L-tryptophan per kg 
body weight.
Blood samples -(approximately 2 ml) were drawn by heart 
puncture or carotid artery cathe.terisation at -5, 5, 10, 25, 30 and 
60 min before or after the initiation of the infusion. They were 
treated as described above (section 6.2.2) and assayed for glucose, 
insulin, glucagon and tryptophan.
f
6.2.4 Infusion of L-tryptophan plus adrenaline
The same solution of L-tryptophan, but this time containing 
36 ng/ml adrenaline (B.P. MacCarthy Ltd., Essex, UK) and 2 mg/ml 
ascorbic acid as adrenaline preservative, was infused in 6 rats 
under the same conditions and experimental protocol as when L- 
tryptophan was infused alone.
6.2.5 Infusion of somatostatin plus L-tryptophan
Somatostatin linear (Somatostatina, Serono, Italy) 
diluted in normal saline was infused in 12 overnight fasted rats 
at a rate of 0.5 yg/min up to a total volume of 1 ml over a period 
of 25 min, using a syringe pump. 15 min after the initiation of 
somatostatin infusion, infusion of L-tryptophan was started in 
6 rats as described in section 6.2.3; in the remaining 6 ratd(controls) 
infusion of normal saline with pH 10.2 raised by addition of NaOH 
was also started 15 min after the start of somatostatin infusion 
and lasted 25 min.
Blood samples were drawn by heart puncture or carotid 
artery catheterisation at -20, -15 (time when the somatostatin 
infusion started), 0, 5, 10, 25, 30, 45 and 60 min before or 
after the start of L-tryptophan or saline infusion.
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Blood glucose, plasma tryptophan, insulin and glucagon levels 
were determined in the samples collected.
6.2.6 Infusion of L-arginine
A constant infusion of a sterilised solution of L-arginine 
at a rate of 0.5 ml/min was given in 6 overnight fasted rats over 
a period of 25 min. The dose used was 0.425 g/kg body weight, a 
dose isomalar to that of L-tryptophan, and the experimental design 
exactly the same as in L-tryptophan infusion study (Section 6.2.3).
Blood glucose levels were measured by a glucose oxidase 
method (GOD-PERID, Boehringer-Mannheim GmbH).
Plasma tryptophan levels were determined by the fluorometric 
method of Denckla and Dewey (208) as adapted for autoanalysis by 
Lewis et al (209) . 100 y 1 of plasma were mixed with 400 yl of 4%
w/v ClgCCOOH and centrifuged at 2500 rpm for 20 min. The super­
natant liquid was decanted and analysed without further dilution.
Plasma insulin, glucagon and "total" glucagon-like immuno- 
reactivity were measured by radioimmunoassay.
Plasma GIP levels were measured by radioimmunoassay technique 
using a second antibody separation system (210).
+The results are expressed as mean - standard error of the 
mean and significance calculated by Student's t-test for unpaired 
data.
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6.3 RESULTS
Intragastric and intravenous administration of L-tryptophan
No significant change was observed in the blood glucose 
levels after intra-gastric injection of tryptophan but intravenous 
injection resulted in a consistent decrease which was statistically 
significant from the control experiments at 30, 45 and 60 min time 
after the administration, as shown in Fig.6.1.
Plasma insulin levels, as depicted in Fig.6.2, increased 
after both routes of administration but they reached higher mean 
values after the oral route.
Tryptophan given orally resulted in a rise of glucagon levels 
(Fig.6.4) which were significantly different from control values at 
5, 10, 30 and 45 min after administration, whereas no significant 
change could be detected after intravenous injection.
A significant increase of plasma GIP levels occurred after 
the orally administered tryptophan (Fig.6.5) which was statistically 
different from control animals at 10 and 30 min (p <0.001 and p <0.01 
respectively).
"Total" glucagon-like immunoreactivity levels (Fig.6.6) 
showed no change when tryptophan was given intravenously and a 
rise recorded after oral administration never became significantly 
different.
Comparing the profiles of plasma tryptophan levels obtained 
after intragastric and intravenous administration (Fig.6.3) it is
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Fig.6.1
Blood glucose levels in response to intragastric (CZU) or intra­
venous administration (ESSJi of L-tryptophan. Dotted bars (£113) 
represent control experiments. Results are the mean ± SEM of 6 
animals. Statistical significance calculated between test and 
control experiments.
*p <0.02, **p <0.01.
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Fig.6.2
Plasma insulin levels in response to intragastric M M  or intra­
venous administration (ESS23) of L-tryptophan. Dotted bars (CIIU) 
represent control experiments. Results are the mean ± SEM of 6
animals. Statistical significance calculated between test and contro 
experiments.
*p <0.05, **p <0.02, ***p <0.01, ****p <0.001.
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Fig.6.3
Plasma tryptophan levels in response to intragastric ( O )  
or intravenous (E223) of L-tryptophan. Results are the mean 
± SEM of 6 animals.
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Fig.6.4
Plasma glucagon levels in response to intragastric (I ~~n or 
intravenous administration (ESS3) of L-tryptophan. Dotted 
bars (Clld) represent control experiments. Results are the 
mean ± SEM of 6 animals. Statistical significance between 
test and control experiments.
*P <0.02, **p <0.01.
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Fig.6.5
Plasma GIP levels in response to intragastric (r i) or 
intravenous administration (E23) of L-tryptophan. Dotted 
bars (2__3) represent control experiments. Results are the 
mean ± SEM of 6 animals. Statistical significance 
calculated between test and control experiments 
* P  < 0 . 0 2 ,  * * p  < 0 . 0 0 1 ,
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Fig.6.6
Plasma "total” glucagon-like immunoreactivity in response to 
intragastric (t__)) or intravenous administration (E5±3) of L- . 
tryptophan. Dotted bars (Cllf) represent control experiments. 
Results are the mean ± SEM of 6 animals.
evident that the corresponding insulin increases were not 
proportional to the rises in tryptophan levels, as comparatively 
small increases detected after intragastric injection resulted in 
higher insulin values than after intravenous injection.
Infusion of L-tryptophan and L-tryptophan plus adrenaline
Infusion of L-tryptophan over*25 min resulted in an increase 
in insulin levels which peaked at 5 min time after the start of 
the infusion, as shown in Fig.6.9. Simultaneous infusion of 
adrenaline resulted in complete inhibition of insulin secretion 
at all time intervals during the infusion despite the higher levels 
of blood glucose recorded during these experiments (Fig.6.8). 
Withdrawal of the infusion was accompanied by an increase in 
insulin secretion in both cases, but was more accentuated after 
tryptophan plus adrenaline becoming significantly different at 
30 min after the start of the infusion (p <0.02).
A fall in plasma glucagon levels was found throughout the 
infusion in both cases, but the fall after tryptophan infusion 
was more pronounced (Fig.6.10) and reached significant difference 
from that observed after tryptophan plus adrenaline at 5 and 
10 min (p <0.01 and p <0.02 respectively).
Infusion of somatostatin plus L-tryptophan
Infusion of somatostatin plus saline (control experiments) 
resulted in a slight drop in blood glucose at the beginning of the 
infusion. At 5 min time (20 min after the start of somatostatin 
infusion) blood glucose rose above basal levels and stayed there 
throughout the experiment (Fig.6.11).
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Fig.6.7 *
Plasma tryptophan levels in response to infusion of L- 
tryptophan (•---•) or L-tryptophan plus adrenaline (O o) .
Results are the mean ± SEM of 
6 animals.
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Fig.6.8
Blood glucose levels in response to infusion of L-
tryptophan (*---•) or L-tryptophan plus adrenaline (o o) .
Results are the mean ± SEM of 6 animals.
*p <0.02, **p <0.002.
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Fig.6.9 .
Plasma insulin levels in response to infusion of L-tryptophan
(©---•) or L-tryptophan plus adrenaline (O-- O) . Results are
the mean ± SEM of 6 animals. .
*p <0.01.
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Fig.6.10
Plasma glucagon levels in response to infusion of L-tryptophan
(•---®) or+ L-tryptophan plus adrenaline : (O o) . Results are
the mean - SEM of 6 animals.
*p <0.02, **p <0.01.
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Fig.6.11
Blood glucose levels in response to infusions of somatostatin and
L-tryptophan (•---•) or somatostatin and saline (a—— o) . Results
are the mean ± SEM of 6 animals.
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Fig.6.12
Plasma tryptophan levels in response to infusions of somatostatin
and L-tryptophan (©---•) or somatostatin and saline (O o) . Results
are the mean ± SEM of 6 animals.
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A drop of plasma insulin and glucagon levels beyond the 
detection limits of the respective assays was found during the 
infusion of somatostatin as shown in Fig.6.13 and 6.14. Plasma 
insulin and glucagon were restored to basal levels after the 
remission of the infusion.
Infusion of tryptophan, started 15 min after the start of 
somatostatin infusion, resulted in an increase in ihsulin levels 
soon after remission of somatostatin which became significantly 
different from control experiments at 25 min (p <0.02) and a 
further suppression of plasma glucagon levels which were different 
from those after infusion of somatostatin plus saline at 25 min 
(p <0.01), 30 min (p <0.02), 45 min (p <0.01) and 60 min (p <0.002).
Infusion of isomolar doses of L-tryptophan and L-arginine
Blood glucose, plasma insulin and glucagon levels after 
infusion of isomolar doses of L-tryptophan and L-arginine are 
shown in Fig.6.15, 6.16 and 6.17. As the experimental protocol 
and conditions under which these infusions took place were the 
same, a direct comparison of the effect of two different amino 
acids on the A- and B-cells of the pancreas can be made. f\jo c^\/ . ^
// V
6.4 DISCUSSION \
Previous studies have demonstrated that intragastric 
administration of amino acids results in a greater rise in 
insulin concentrations than that obtained after intravenous 
administration (213) . The data obtained in the present invest­
igations confirm the differential pancreatic B-cell response
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Fig.6.13
Plasma insulin levels in response to infusions of somato­
statin and L-tryptophan («---•) or somatostatin and
saline (o O) . Results are the mean ± SEM of 6 animals.
*p <0.02.
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Fig.6.14
Plasma glucagon levels in response to infusions of somato­
statin and L-tryptophan (•---•) or somatostatin and saline
(O o) . Results are the mean ± SEM of 6 animals.
*p <0.02, **p <0.01
Bl
oo
d 
gl
uc
os
e 
m
m
o
l
/
1
150
8
7 --
5  --
 -i j 1---1---1---1---1---1 — I---1 ; -f H
0 10 20 30 40 50 _   60
Time (min) after the start of the infusion
Fig.6.15 -
Blood glucose levels in response to infusion of L-tryptophan
(®— — ®) or L-arginine (O o) in isomolar doses.
Results are the mean ± SEM of 6 animals.
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Fig.6.16
Plasma insulin levels in response to infusion of L-tryptophan
(& o) or L-arginine (o o) in isomolar doses.
Results are the mean ± SEM of 6 animals.
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Fig.6.17
Plasma glucagon levels in response to infusion of L-tryptophan
(©---©) or L-arginine (o o) in isom.olar doses.
Results are the mean ± SEM of 6. animals.
to intragastric and intravenous tryptophan, but suggest a possible 
role for GIP in mediating this effect. These results are in 
agreement with results reported by Thomas et_ al (212) according to 
which intraduodenal amino acid administration stimulated the 
secretion of GIP whose possible role in the enteric mediated 
release of insulin was suggested.
Gut glucagon-like immunoreactivity (GLI) released by glucose 
ingestion and a variety of intraduodenal stimuli has also been 
suggested as the enteric factor augmenting the B-cell response to 
ingested glucose (72). Although GLI released by non-glucose stimuli 
has not been accompanied by a rise in plasma insulin, even when 
blood glucose levels were maintained well above normal by a . 
simultaneous intravenous infusion of glucose (117) , its role as a 
mediator of the entero-insular axis could not be excluded from the 
data of the present study.
A possible explanation for the different pattern of plasma 
glucagon levels obtained after intragastric and intravenous admin­
istration could be the glucagonotropic action of GIP. Taminato 
et al (213) found a much larger rise in peripheral plasma glucagon 
than in plasma insulin levels after administration of synthetic 
GIP to fasted rats. These results raise the possibility that GIP 
might in fact exert its effect mainly, or even exclusively, by 
promoting glucagon release from pancreatic A-cells which in turn 
stimulate insulin release.
Adrenaline infused simultaneously with tryptophan at a dose 
found to inhibit insulin release in response to intravenous glucose, 
infusions in the rat, did inhibit insulin release in response to
tryptophan stimulation. This finding, v/hich is in contrast to 
findings reported by. Conway et cil (207) who failed to find insulin 
inhibition after alanine stimulation, does not lend any further 
support to the concept that amino acids act through alternate 
pathways different from those utilised by glucose to effect insulin 
secretion.
f
The hypoglycaemic effect of tryptophan when given as an 
infusion and to a smaller extent after intravenous flash injection, 
as well as the accompanied inhibition of glucagon secretion, could 
not be explained in this context. Reports that tryptophan causes 
inhibition of gluconeogenesis (214) (215) at the locus of phospho-
enolpyruvate carboxykinase were argued by Smith and Pogson (216) 
who suggested that the hypoglycaemic effect of tryptophan is not 
direct but is mediated via one or more of its metabolites. Darwish 
et al (217) suggested that this effect may be mediated through 
the accumulation of 5-hydroxy tryptophan in the central nervous 
system as there is evidence that stimulation of central 5-hydroxy- 
tryptamine receptors inhibits the secretion of ACTH and increases 
the secretion of prolactin which could contribute towards the 
production of hypoglycaemia.
Infusion of somatostatin before and during the infusion of 
tryptophan resulted in inhibition of insulin secretion after trypto­
phan stimulation. Despite the presence of huge tryptophan concent­
rations and hyperglycaemia, the inhibitory effect of somatostatin 
on A- and B-cells of the pancreas proved to be very potent, as already 
reported by Alberti et al (218) and Gerich et al (219).
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Finally, the differences in the insulinotropic and 
glucagonotropic activity of individual amino acids as illustrated 
by direct comparison of insulin and glucagon responses after iso­
molar infusions of L-tryptophan and L-arginine could not be 
explained.
. CHAPTER 7 
FINAL DISCUSSION AND CONCLUSIONS
7.1 THE ROLE OF GLUCAGON IN GLUCOSE HOMEOSTASIS
The concept that glucagon and insulin jointly regulate 
glucose homeostasis'in normal physiology is particularly 
attractive. And it becomes more attractive when explanations for 
the pathogenesis of the diabetic syndrome are sought, as it has 
been suggested that diabetes results not from insulin lack by 
itself but rather from bihormonal disturbance of Ay- and B-cell 
function (220) (38).
Studies with the use of doses of glucagon which are 100-1000 
times the normal secretory rate have suggested that glucagon is a 
potent insulin antagonist in man. Glucagon consistently stimulates 
glycogenolysis and gluconeogenesis in vitro (64). In intact man, 
supraphysiological doses of glucagon (causing plasma levels of 
5000 pg/inl) augment splachnic output of glucose and cyclic AMP 
(221). Although the pharmacological effects of glucagon on 
glucose homeostasis are well established, the significance of 
these observations to normal physiology has recently been questioned.
Studies using physiological doses of glucagon (3 ng/kg/min) 
in normal subjects, which result in increments in plasma glucagon 
comparable to those reported in a variety of hyperglucagonaemic 
states produce only small, transient increases in blood glucose 
levels (222). Blood glucose concentration returns to basal levels 
within 2-3 h despite hyperglucagonaemia and normal peripheral levels 
of insulin (222). The transient rise in blood glucose after 
physiological infusions of glucagon is a consequence of a very 
evanescent increase in splachnic glucose production. In response
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to physiological increments in glucagon, splachnic glucose output 
rapidly increases by 2-3 fold within 7-15 min, but returns to 
base line levels wi.thin 30 minutes (223) .
In contrast to glucagon, the effects of physiological 
increments in plasma insulin persist during periods of insulin 
administration lasting 1 hour or more and continue for 30-45 min 
after cessation of. an insulin infusion (224) (225) . These
differences in time course of the biological action of physiological 
perturbations in glucagon and insulin raise serious questions 
regarding the significance of the insulin to glucagon ratio in 
determining normal glucose homeostasis (226).
The bihormonal response (hyperinsulinaemia and hypoglucagon- 
aemia) to ingestion of large carbohydrate loads has prompted 
speculation that the combined A- and B-cell response, i.e. the 
insulin to glucagon ratio, rather than changes in insulin alone, 
may be required for normal glucose disposal. That the rise in 
insulin is essential for normal glucose disposal is indisputable 
as attested by the effects of pancreatectomy, alloxan and 
streptozotocin. On the other hand, evidence for the essentiality 
of glucagon suppression has ^been entirely indirect.
When the effects of physiological hyperglucagonaemia and 
an altered insulin to glucagon ratio on oral glucose tolerance 
were evaluated in normal subjects, the concept of bihormonal 
regulation was not supported. To evaluate the essentiality of 
glucagon suppression in, normal glucose tolerance, glucagon was 
infused in physiological amounts (3 ng/kg/min) prior to and 
during oral glucose tolerance testing. Rather than the usual fall
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in plasma glucagon accompanying carbohydrate feeding, 3-4 fold 
increments in plasma glucagon were maintained (222) , but glucose 
tolerance was not different from that observed during a control 
study in which saline solution was infused. Particularly 
interesting was that normal glucose tolerance was maintained in 
the absence of compensatory hyperinsulinaemia.
These findings showed that the fall in plasma glucagon 
observed after carbohydrate feeding is not essential for the 
maintenance of normal glucose tolerance. They indicate that the 
primary determinant of normal glucose disposal is the insulin 
secretory response and that the insulin to glucagon ratio provides 
a no more useful index of glucose homeostasis than is availab’le 
from the absolute concentration of insulin.
In the present study, neutralisation of circulating glucagon 
by glucagon antibodies in fasted rats failed to depress basal 
blood glucose levels. These results, in agreement wich other 
studies (166) (168), indicate that the absolute concentration of
glucagon in plasma is of minor importance for the maintenance of 
basal blood glucose. If, as it is thought, glucagon during fasting 
initiates hepatic glucose production through hepatic glycogenolysis 
and hepatic gluconeogenesis in order to meet the fuel demands of 
the periphery, one would expect a transient hypoglycaemia to 
develop. Also, glucagon antibodies failed to slow down the 
recovery of insulin-induced hypoglycaemia which is considered to 
be the most potent stimulus to glucagon secretion. These findings 
suggest that the rise in glucagon secretion after insulin-induced 
hypoglycaemia is a result of failure of negative feed-back control
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of A-cell secretion due to inhibition of B-cell secretion soon 
after the institution of hypoglycaemia (40). The role of glucagon 
in the recovery from hypoglycaemia did not prove to be major and 
these results indicate that other counter-regulcitory hormones, as 
catecholamines, may play a more important role than glucagon.
Finally, conditions associated with hyperglycaemia, as those 
resulting after administration of 2-deoxy-gJ.ucose or diazoxide, 
attributed by early studies to increased secretion of glucagon 
(227) (6) are not still considered to be mediated by glucagon.
Recent data showed a suppressive effect of diazoxide on glucagon 
secretion in vitro (228) (229) as well as in vivo (230). Also,
no involvement of glucagon could be demonstrated in the hyper— 
glycaemic effect I2-deoxy-glucose (174),
7.2 THE ROLE OF GLUCAGON IN THE REGULATION OF INSULIN SECRETION
The finding that glucagon is one of the most potent direct 
stimuli to insulin secretion known, created difficulties in 
reconciling this new role of glucagon with the up-to-then well- 
accepted role of glucagon in glucose homeostatic control was put 
forward ( 6 )  (45)/ according to which a major role of glucagon
in man is to regulate insulin secretion.in response to the ingestion 
of food without the necessity for comparatively large changes in 
substrate concentration in the blood. According to this hypothesis, 
glucagon acts as a.signal sensor and amplifier of certain stimuli 
to insulin secretion, thereby enormously increasing the sensitivity 
of the insulin-secreting system to insulin requirements.
A major obstacle to more general acceptance of this theory 
was the difficulty to demonstrate that the secretion of glucagon
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normally precedes that of insulin release when islets are 
stimulated by their mutual secretagogue, arginine or amino 
acids (231) (232), and also that glucose, a major regulator
of. both cell types in vivo and in vitro, stimulates insulin release 
during attendant inhibition of glucagon secretion. However, quite 
recently Pek and his colleagues (233) have demonstrated, using the 
isolated perfused rat pancreas preparation, that glucagon release 
does precede insulin release in response to a number of common 
secretagogues. Another piece of evidence that glucagon precedes 
insulin secretion, is coming from the work of Dencker et_ al (234). 
They studied insulin and glucagon release in portal venous blood, 
sampled through an indwelling catheter in three human subjects in 
response to the ingestion of a test mixed meal. In two of the 
three subjects portal venous plasma glucagon concentrations 
showed an early increase before decreasing to below basal values 
as insulin concentrations rose.
In the present study neutralisation of circulating glucagon 
by glucagon antibodies after arginine stimulation in rats almost 
abolished the insulin response observed in rats administered non- 
immune serum. To a lesser extent abolition of insulinotropic 
activity of arginine occurred in rabbits immunised against glucagon.
In the light of these new findings, the once proposed bi­
hormonal hypothesis for the regulation of blood glucose levels 
(Fig.7.la) has to be modified, and presented in "control theory" 
terms is schematised in Fig.7.lb.
Finally, the effect of unabsorbable carbohydrate, as guar 
gum (Chapter 3), to diminish insulin responses when added to meals
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and the role of "total" GLI in this differential insulinaemic 
response is not conclusive from the data of this study. The 
numbers of sub jects - used in this study were not adequate to 
establish "total" GLI, a plausible insulin secretagogue, as a 
convincing determinant of insulin responsiveness, but neither 
were they adequate to exclude it.
7.3 GLUCAGON AND ENTEROINSULAR AXIS
The role of glucagon in the mechanism of the stimulatory 
effect of gut hormones on insulin secretion is not clear. It 
had been postulated (6) that in man and other mammals in which 
A- and B-cells occur in the same islets, glucagon might be one, 
not necessarily essential, step in the cascade amplification 
of the augmenting signal to insulin secretion transmitted from 
the gastrointestinal tract to the pancreas in response to the 
ingestion of food.
The immunochemical observations of Smith et al (234) and 
Garaud et al (235) that in some species glucagon immunoreactive 
cells in the pancreatic islets react also with GIP antiserum, 
even in the presence of excess exogenous glucagon have been 
recently confirmed with a GIP antiserum not cross-reacting with 
glucagon (186). Considering these observations, it has been 
suggested that the A-cells contain both hormones, though whether 
the immunoreactive GIP is produced by the A-cells or transported 
from the gut and absorbed onto receptors on the surface of the 
A-cell is uncertain.
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Indirect evidence that GIP, the currently favoured mediator 
of enteroinsular axis,<might in fact exert its effect mainly, or 
even exclusively by promoting glucagon release from pancreatic 
A-cells is that the insulinotropic effects of exogenous GIP are, 
like those of glucagon, discernible only in the presence of mild 
to moderate hyperglycaemia. Under experimental conditions, 
synthetic GIP administered to fasting rats produced a relatively 
much larger rise in peripheral plasma glucagon than in plasma 
insulin levels, a situation that was completely reversed when 
induced hyperglycaemia was present (213). The insulinotropic 
effects of GIP in this case were dominant and the glucagon 
stimulatory effect of GIP was manifested only as a failure to 
observe the usual fall in plasma glucagon levels produced by the 
insulin release.
However, the stimulation of glucagon release by GIP has 
been questioned recently. Using the glucose clamp technique, 
exogenous GIP given in physiological and supraphysiological doses 
did not stimulate glucagon release in man (236) . The high 
insulin levels recorded in this study could account for the 
failure of GIP to stimulate glucagon. Endogenous GIP released 
by fat ingestion was also reported to have no glucagonotropic 
activity during hypoglycaemic, euglycaemic and hyperglycaemic 
clamps (2 37).
In the present study tryptophan given orally in fasting rats 
resulted in a considerable rise of GIP levels and a large and 
sustained insulin secretion. When given intravenously a smaller 
increase in insulin levels occurred despite the fact that the
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stimulus (plasma levels of tryptophan) was always bigger in 
this group of rats. A drop in plasma glucagon levels was found 
after intravenous administration of tryptophan but a slight rise 
in pancreatic glucagon occurred when tryptophan was given orally.
The evidence is good enough to indicate that GIP released 
from the gut in response to the ingestion of tryptophan exerted 
its effect by promoting glucagon release from pancreatic A-cells. 
This amplified the signal to insulin secretion, as pancreatic 
glucagon is an extremely potent local paracrine stimulus to 
insulin, resulting in a more efficient and rapid assimilation of 
the ingested nutrient.
However, more hard evidence is required to unravel the role 
of glucagon in the enteroinsular axis and its interrelationship 
with grastrointestinal hormones as well as other insular hormones.
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